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Introduction 
 
1 Introduction 
1.1 The Hypothalamic-Pituitary-Adrenocortical Axis 
1.1.1 Overview of Function 
All organisms strive towards maintaining their homeostasis, i.e. the dynamic 
equilibrium of their internal milieus that is essential for survival. The challenge of 
homeostasis by internal or external factors is classically referred to as “stress”. 
“Stress reaction” is the response of an organism to stress and spans from local 
biochemistry to global behavior. In mice and men, the sympathetic nervous system 
and the hypothalamic-pituitary-adrenocortical (HPA) system are the central 
regulators of the stress response (de Kloet et al., 2005). The HPA axis is formed by 
three main structures: the hypothalamus, the pituitary and the adrenal gland.  
 
The hypothalamus is located below the thalamus along the walls of the third ventricle 
and has multiple roles in the maintenance of homeostasis. For the mediation of the 
stress response, parvocellular neurons from the paraventricular part of the 
hypothalamus are of crucial importance. They secrete corticotropin-releasing 
hormone (CRH, also CRF: corticotropin-releasing factor) into the pituitary portal 
vessels. The pituitary gland is situated in the sella turcica and consists of three lobes, 
an anterior, an intermediate and a posterior lobe. Upon CRH stimulation, endocrine 
cells from the anterior lobe of the pituitary release adrenocorticotropic hormone 
(ACTH) into the general circulation. With the blood flow, ACTH reaches the adrenal  
glands which are located on the upper pole of the kidneys. The adrenal glands 
comprise two organ compartments, the adrenal medulla and the adrenal cortex. 
While the medulla forms part of the sympathetic nervous system, the cortex is the 
body’s major source of steroid hormones. Of these, mineralocorticoids are 
synthezised in the glomerular layer, glucocorticoids in the fasciculate layer and 
adrenal androgens in the reticulate layer of the human adrenal cortex. ACTH 
stimulation results in release of adrenal glucocorticoids that are key mediators of 
stress response (Bear et al., 1996).  
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Glucocorticoids, of which cortisol is of most importance in humans, exert their 
pleiotropic effects on metabolism, the immune system and cognitive function by 
binding to cytosolic glucocorticoid receptors (GR) and mineralocorticoid receptors 
(MR). These receptors regulate the transcriptional activity of genes by binding to 
glucocorticoid-response elements (GREs) in promoter regions. In contrast, rapid 
actions of glucocorticoids are transduced by membrane bound receptors (Dallman, 
2005;Norman et al., 2004). In the brain, glucocorticoid-regulated genes are involved 
in neuronal metabolism, connectivity and synaptic transmission (de Kloet et al., 
2005). The release of adrenal glucocorticoids is tightly controlled by negative 
feedback mechanisms within the HPA axis (see figure I1).  
 
 
 
While structure and function of the HPA axis are essentially the same in mouse and 
human, the mouse lacks expression of steroid 17α-hydroxylase (CYP17) in the 
adrenal, an enzyme essential for the generation of cortisol and androgens. Therefore 
the main glucocorticoid in the mouse is not cortisol but corticosterone and adrenal 
androgens are not synthezised (Parker and Schimmer, 2001). How the HPA axis and 
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more specifically, how the adrenal cortex and adrenal glucocorticoids, are involved in 
the pathophysiology of depression will be described in the following section. 
 
1.1.2 The HPA Axis and Depression 
Major depressive disorder (MDD) is a chronic, recurring and potentially life-
threatening illness. According to the WHO world health report 2002 it accounts for 
4.4 percent of the total overall disease burden, which is similar to the contributions of 
ischemic heart disease or diarrheal diseases (Mann, 2005). Besides being a highly 
disabling condition in itself, MDD patients have an increased risk of death from 
suicide, accidents, respiratory disorders, stroke and heart disease. Conversely, 
effective treatment of depression lowers the risk of suicide and improves the outcome 
after stroke and acute myocardial infarction (Mann, 2005). From the psychiatric as 
well as the somatic medical perspective, adequate treatment for depression therefore 
seems highly indicated. However, current treatment options are still not optimal as 
the molecular pathology of depression remains largely unknown despite extensive 
research efforts. Amongst others, contributions of several neurotransmitter systems 
including the monoaminergic system, neurotrophic factors, the endogenous opioid 
and cannabinoid systems and several neuropeptides have been demonstrated 
(Ebmeier et al., 2006) as well as differences in intracellular signaling cascades (Manji 
et al., 2001) up to the recent discussion of a possible role for chromatin organization 
(Berton and Nestler, 2006). However, by far the most robust and well-studied somatic 
changes in depression are changes in HPA hormone secretion.  
 
Morphologically, an increase in adrenal volume as measured by computed 
tomography has been reported in depressed patients which was reversible by 
antidepressant-treatment (Nemeroff et al., 1992;Rubin et al., 1995). Paraclinical 
evidence for a feedback impairment in HPA axis regulation comes from abnormalities 
in a variety of functional neuroendocrine tests such as the combined dexamethasone 
suppression/CRH stimulation test (Holsboer, 2000;Holsboer, 2001). Indeed, HPA 
axis hyperreactivity was even found to be a predictor for relapse into a depressive 
episode within the six months following hospital discharge (Zobel et al., 1999). 
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Recently, the use of the GR antagonist mifepristone in the treatment of psychotic 
depression has been successfully tested in a small randomized, placebo-controlled, 
double-blinded study, providing additional clinical evidence for the importance of HPA 
signaling in depression (Flores et al., 2006).  
 
On the level of preclinical research, multiple mouse models with either disrupted or 
increased expression of key HPA axis molecules have been developed to 
experimentally elucidate HPA axis functioning (Keck et al., 2005). These models 
have become increasingly more sophisticated and have reached the level of tissue 
specificity. An example for such an approach with respect to glucocorticoid signaling 
is the mouse model of conditional gene disruption of the glucocorticoid receptor (GR) 
in the forebrain. Even though the GR is left intact in the hypothalamus and the 
pituitary, GR disruption in forebrain in this model nonetheless leads to impaired 
negative feedback regulation of the HPA axis and increased depression-like behavior 
in behavioral paradigms (Boyle et al., 2005). Forebrain specific GR overexpression 
on the other hand results in increased anxiety-like behavior and an overall increased 
emotional lability (Wei et al., 2004). 
 
A direct involvement of the adrenal gland in the pathology of depression can 
therefore be deduced both from abnormalities in cortisol secretion in patients as well 
as from findings in animal models. Notably, regulation of adrenal glucocorticoid 
secretion is more complex than postulated in the classical model, where cortisol is 
released upon ACTH stimulation (see figure I1) (Ehrhart-Bornstein et al., 1998). It is 
now known that glucocorticoids enhance the expression of steroidogenic enzymes in 
the adrenal constituting an ultra-short feed-forward loop (Feltus et al., 2002). On the 
other hand, corticosterone release after ACTH administration is dependent on CRH 
signaling via CRHR1, as was shown in CRHR1 knock-out mice (Muller et al., 
2001;Timpl et al., 1998). The latter findings directly point toward the existence of an 
intra-adrenal regulatory CRH system.  
 
In conclusion, the adrenal is receiving increasing attention in psychiatry and somatic 
medicine especially as evidence about the connection between major depressive 
disorder and somatic illnesses such as coronary heart disease is accumulating (Joynt 
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et al., 2003). As glucocorticoids exert their effect on a multitude of central as well as 
peripheral targets, they could represent the missing link between the different 
pathologies (Brown et al., 2004). Deepening our understanding of function and 
regulation of the central steroid-hormone-producing organ, the adrenal gland, will 
therefore be of great value. For this purpose, constructs for the germline-
transmissable genetic manipulation of mice are generated in this thesis and applied 
to the mouse, that allow advanced functional genetic experiments in the murine 
adrenal. How mice contribute to our knowledge of psychiatric disorders will be 
outlined in the following section. 
 
1.2 Genetic Mouse Models in Psychiatric Research 
The existence of a genetic component in the pathogenesis and maintenance of 
psychiatric disorders has long been recognized from twin and adoption studies. 
Nowadays, genetic linkage analysis even allows the precise identification of genetic 
loci involved in a pathology (Inoue and Lupski, 2003). In combination with information 
on the human genome sequence this represents an invaluable resource for 
understanding human disease processes. It is however for technical and ethical 
reasons impossible to systematically manipulate genes in humans. In order to learn 
about human gene function we must therefore take advantage of model organisms 
such as the mouse.  Mice in somatic medical and psychiatric research allow a variety 
of experiments including genetic engineering and behavioral testing. Compared to 
invertebrate model organisms, mice show a much wider range of social and 
emotional behaviors that are essential for the understanding of psychiatric illness. 
Genetically engineered mice can be rigorously tested to study the effects of a genetic 
mutation on the animal’s behavior, cognition, physiology and response to 
pharmacological agents (Bucan and Abel, 2002;Seong et al., 2002).  
 
As fellow mammals, mice and humans possess a similar anatomy and physiology. 
Furthermore, genomic analysis indicates that a mouse gene equivalent, an 
orthologue, exists for about 99,5% of human disease genes, amongst which the ones 
with neurological function exhibit the highest grade of evolutionary conservation 
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(Huang et al., 2004). In addition, murine genes are often located on the 
chromosomes in a syntenic manner, i.e. in regions with the identical chromosomal 
arrangement of genes as in humans. This high level of genetic homology underlines 
the theory that humans differ from other mammals rather by the complexity of gene 
regulation than by the number or composition of their genes. 
 
A putative gene function is usually deduced from a phenotype that derives from 
either excessive or abolished function of the gene of interest, i.e. from either gain-of-
function or loss-of-function experiments. In principle, this genetic approach offers 
much higher specificity than the classical pharmacological experiments based on 
small-molecule compounds as single genes are precisely targeted. From the 
experimenters point of view, the availability of inbred mouse strains that diminish 
genetic background heterogeneity on experimental read-out variables has proven 
particularly useful (Tecott, 2003). Furthermore, mice are excellent experimental 
animals as their reproductive rate is high and their physical size is low, allowing the 
maintenance of large groups of animals (Sung et al., 2004). Finally, the online 
availability of the complete mouse genome sequence permits convenient 
experimental design and bioinformatic comparison with the human genome 
sequence. 
 
A variety of different mouse models have been established revolutionizing our 
understanding of the pathophysiology of many diseases. In psychiatry, the range of 
models covers the entire spectrum of disease. Phenotypes mirroring such diverse 
entities as Brunner’s syndrome (Brunner et al., 1993;Cases et al., 1995), severe 
language disorder (Lai et al., 2001;Shu et al., 2005), trichotillomania (Greer and 
Capecchi, 2002) and narcolepsy (Chemelli et al., 1999) could be generated by 
modification of single genes in the mouse. Moreover, complex syndromatical 
disorders like substance dependence, schizophrenia and depression have also been 
modelled with great success (for reviews see (Cryan and Holmes, 2005;Cryan and 
Mombereau, 2004;Ellenbroek, 2003;Nestler, 2000;Seong et al., 2002). 
 
Although mice serve as valid models for many aspects, they cannot possibly mimic 
all the complex facettes of human psychiatric disease. Above all, the common 
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multifactorial genesis of many psychiatric disorders, involving environmental 
variables exerting their effects on the background of a complex genetic susceptibility, 
can so far only be partly accounted for. Current rodent models are therefore best 
used to examine certain disease sub-features, so called “endophenotypes”, i.e. 
measurable biological traits that are associated with target behavioral phenotypes 
(Hasler et al., 2004). 
 
Modelling DSM-IV symptoms of major depressive disorder in mice 
Symptom Possible modelling paradigm 
Markedly diminished interest or pleasure 
in everyday activities (anhedonia) 
Reduced intracranial self-stimulation or 
ad-libitum sucrose intake 
Marked changes in appetite or weight Abnormal loss of weight after exposure to 
chronic stressors 
Insomnia or excessive sleeping Abnormal sleep architecture in the EEG 
Psychomotor agitation or slowness of 
movement 
Alterations in locomotor activity and motor 
function 
Fatigue or loss of energy Reduced activity in home cage, tread mill 
running activity or nest building  
Indecisiveness or diminished ability to 
think or concentrate 
Deficits in working or spatial memory and 
impaired sustained attention 
Difficulty performing even minor tasks,  
e. g. leading to poor personal hygiene 
Poor coat condition during chronic mild 
stress 
Depressed mood Cannot be modelled 
Recurrent thoughts of death or suicide Cannot be modelled 
Feelings of worthlessness or excessive or 
inappropiate guilt 
Cannot be modelled 
 
Table 1: Modelling DSM-IV symptoms of major depressive disorder in mice (adapted 
from Cryan and Holmes, 2005) 
 
As table 1 shows, mice lack some of the unique human functions such as awareness 
of one’s self or suicidality, whose impairments form integral parts of psychiatric 
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disorders, or as Keck and colleagues put it “… it is now very unlikely that we will ever 
be able to diagnose a rodent according to the algorithms given by ICD-10 or DSM-IV” 
(Keck et al., 2005). When compared to rodents, disparities in cortical and other 
neural structures enable humans to react with a wider range of behavior in a given 
situation and may also increase their adaptive capacity towards a genetic 
modification. On the other hand, the neurobehavioral consequences of certain 
genetic mutations may be more readily detectable in humans due to the availability of 
self-report data and the stringent functional requirements of our highly complex 
human society (Tecott, 2003). In conclusion, despite species-inherent limitations, 
genetic mouse models have proven highly useful for somatic medical and psychiatric 
research. How the mouse genome can be manipulated for research purposes and 
what strategies were chosen for this thesis will be described in the next section. 
 
1.3 Manipulating the Mouse Genome 
1.3.1 The Phenotype-Based Approach 
The historic roots of selective mouse breeding for desired phenotypes such as 
specific coat colors date back to 18th century China and Japan where collectors held 
mice as pets. This custom was adopted in Europe and imported mice from the Far-
East were bred to local mice. In the beginning of the 20th century, pioneers of mouse 
genetics, such as Castle and Little, recognized the applicability of the Mendelian laws 
for coat color inheritance in the mouse. Their increasing demand for laboratory mice 
led to the establishment of the first mouse-breeding farm by Abbie Lathrop in Granby, 
Massachusetts. The mouse inbred lines founded by Lathrop are derived from 
crosses of imported East-Asian “fancy” mice and European mice and represent the 
origin of most strains of modern inbred laboratory mice (Wade and Daly, 2005). 
  
Today, the phenotype-based approach of manipulating the mouse genome as in the 
past still relies on the same principles of selection and interbreeding of mice with 
particular phenotypes of interest. It is then however complemented by a genetic 
analysis in order to identify the genetic modifications contributing to the observed 
phenotype. The LAB-M and HAB-M mice are one example for this strategy in 
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psychiatric research. These mice were selectively bred for either low- or high-anxiety-
related behavior which led to the discovery of glyoxalase-I as protein marker in trait 
anxiety (Kromer et al., 2005). On a larger scale, the phenotypic approach is pursued 
by n-ethyl-n-nitrosourea (ENU) mutagenesis projects. ENU treatment induces 
random genomic point mutations at a high rate. ENU-mice that show a phenotype of 
interest are selectively bred and the genetic locus involved is mapped (Keays and 
Nolan, 2003). ENU mutagenesis enabled the functional characterization of the clock 
gene which is fundamental for circadian rhythmicity (Vitaterna et al., 1994). Clock 
also forms part of a group of genes in which certain polymorphisms are associated 
with seasonal affective disorder (Johansson et al., 2003). It also modifies exploratory 
behavior in mice, a parameter indirectly reflecting anxiety (Easton et al., 2003). 
Interestingly, it has recently been shown by the more elaborate approach of cre/lox 
mediated site-directed mutagenesis that even in the absence of clock certain 
circadian systems remain intact (Debruyne et al., 2006). This example points to the 
crucial importance of tissue-specific gene disruptions to study gene function as will 
be discussed later. 
 
1.3.2 Transgenic Mice 
The term “transgenic mouse” as employed in this work refers to a mouse that is 
derived entirely from the successive cell divisions of a fertilized one-cell egg into 
which foreign DNA is introduced by microinjection (Palmiter et al., 1982). The foreign 
DNA constructs usually consist of a gene of interest linked to promoter and 
regulatory sequences that direct the spatial and temporal pattern of transgene 
expression. After microinjection, integration of foreign into host DNA occurs at 
random. The manipulated oocytes are surgically transferred into the uteri of foster 
mothers, which give birth to offspring entirely derived from the engineered oocyte. As 
the resulting transgenic mice carry the genetic modification in every cell including 
their germ cells, they can subsequently be used as founding breeders to transmit the 
genomic modification into the next generations (Wells and Murphy, 2003). Notably, 
integration by transgenesis is an additive process: The host genome gains new 
information. Therefore transgenesis is per se a more feasible technique to conduct 
gain-of-function rather than loss-of-function experiments. One of many prominent 
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examples for the transgenic approach to model a human neuropsychiatric disease 
was the generation of the first mouse model for the polyglutamine expansion disease 
Huntington’s chorea (Mangiarini et al., 1996). The generation of transgenic mutations 
for all existing genes is currently pursued by “gene trapping” through large 
international consortia (Schnutgen et al., 2005). 
 
A limitation of the transgenic approach is the essentially random integration into the 
genomic DNA of the recipient egg. Therefore the undesired disruption of a native 
gene may confound the interpretability of the resulting phenotype. However, the 
random nature of transgene integration may as well lead to serendipitous insights 
into the function of unintentionally mutated genes as in the case of the MAOA gene 
(Cases et al., 1995). Multiple transgene integration as head-to-tail repeats in a single 
integration site is a second caveat. Depending on the number of integrants this will 
result in differing expression levels. Gene dosage is furthermore affected by the 
sequence environment of the integration site: If integration takes place in a highly 
transcribed genetic region, it is likely that the level of transgene transcription is also 
high and vice versa (al-Shawi et al., 1990). Moreover, completely unexpected tissue 
patterns of transgene expression may arise due to local modulators of transgene 
promoter activity depending on the site of integration (Tan, 1991). Such positional 
and copy number effects can be minimized by using bacterial artificial chromosomes 
(BACs) or similar transgene constructs as presented in this work (Heintz, 2001). 
 
1.3.3 Gene Targeting 
“Gene targeting” refers to DNA integration via homologous recombination between a 
specifically designed targeting construct and a DNA sequence of interest. The 
development of mouse gene targeting in the late 1980s by the groups of Evans, 
Smithies and Capecchi marks an enormous extension of the tool set for genetic 
manipulations. Gene targeting allows the precise integration of an engineered 
genetic construct into a predetermined position of the mouse genome. This technique 
has been most frequently used to generate “knock-out” mice, i.e. mice in which the 
function of an endogenous gene is selectively disrupted by the insertion of an 
exogenous construct. 
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First step of the gene targeting procedure is the incorporation of a genetic construct 
into murine embryonic stem cells (ES cell) by exposure to an electric pulse. Once 
inside the nucleus of the ES cell, the external DNA is integrated into the specific 
genomic locus by the homologous recombination machinery of the ES cells. Stem 
cell clones with the desired mutation are selected and microinjected into wildtype 
mouse blastocysts or aggregated into wildtype morulae where they form mosaic 
embryoblasts, that in part derive from wildtype cells, in part from engineered cells. 
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These mosaic blastocysts are then transplanted into pseudo-pregnant mice that give 
birth to mosaic animals, commonly termed “chimeras”. In case the germ cells of 
these chimeras derive from the mutant cells, they can be used as founding breeders. 
Half of their offspring will be heterozygous for the desired mutation in every cell of 
their organism (see figure I2). 
 
In our group, gene targeting was successfully used to elucidate the function of 
corticotropin releasing hormone receptor 1 (CRHR1). In this experiment, CRHR1 
function was disrupted by replacing CRHR1 exons 5-7 by a neomycin resistance 
cassette. The resulting animals, devoid of CRHR1 in their entire organism, show 
pronounced reduction of ACTH and corticosterone release following stress, 
differences in adrenal morphology and reduced anxiety-related behavior (Smith et al., 
1998;Timpl et al., 1998). Another classical example of gene targeting in psychiatric 
research are the presenilin-1 deficient mice generated by Shen and colleagues 
modelling a familial form of Alzheimer’s disease (Shen et al., 1997).  
 
Besides the generation of such null mutations by introducing selectable marker 
cassettes, gene targeting permits the introduction of more subtle changes, such as 
point mutations as the wildtype alleles are being specifically replaced by an external 
DNA. With their α1H101R mice, for example, McKernan and colleagues could show 
that the replacement of a single amino acid in the α1 subunit of the GABAA receptor 
abolishes the sedative but not the anxiolytic effect of diazepam (McKernan et al., 
2000). Such a “knock-in“ strategy even allows the introduction of genes that are 
entirely unrelated to the targeted wildtype gene as is in this work where a cre 
recombinase encoding gene is inserted into the adrenocorticotropin receptor locus. 
The cre transgene will therefore take advantage of the wildtype regulatory elements 
at the targeted locus, resulting in an expression pattern thought to equal the 
expression pattern of the receptor for adrenocorticotropic hormone. 
 
As in the classic transgenic animals described earlier, a limitation of mice generated 
by gene targeting is that the introduced genetic modifications are present and 
possibly active from conception onwards, through embryonic development into 
adulthood. As a consequence, a resulting phenotype either reflects the adult function 
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of the gene or its role during development or a combination of both. In the most 
drastic case, an embryonic lethal phenotype of a targeted gene may preclude the 
study of a phenotype in the adult animal. As a consequence, “conditional” or 
“inducible” mutagenesis was developed, which permits initiation of transgene 
expression in a specific sub-population of cells and at specific time-points during or 
after embryonic development (Wells and Murphy, 2003). 
 
1.3.4 Conditional Control of Gene Expression 
“Conditional” and “inducible” control of gene expression, i.e. control in a cell-type-
specific and/or time dependent manner, can be achieved either on DNA sequence 
level or on the level of RNA transcription. Employing these techniques, the tissue-
specific function of genes can be studied independent of confounding effects of 
possible gene functions in other tissues. Transcriptional transactivation relies on 
either the lac operon (Scrable, 2002) or tetracycline (tet) based systems (Gossen et 
al., 1995) and is reversible as the DNA sequence itself remains unaltered. A recent 
example for the application of the tet system to conditionally model a psychiatric 
disease is the generation of mice overexpressing the dopamine receptor D2 in the 
striatum (Kellendonk et al., 2006), mimicking the single photon emission computed 
tomography (SPECT) observation of increased striatal D2 receptor occupancy in 
schizophrenic patients (bi-Dargham et al., 2000). Amongst other phenotypes, these 
mice have defects in working memory, a cognitive parameter associated with 
prefrontal cortex function, which is known to be impaired in schizophrenic patients. 
On DNA level, conditional control of gene expression is realized by the application of 
site-specific DNA recombinases such as cre, flp or ΦC31. Of these, cre recombinase 
has found by far the most widespread use in the mouse and is also used in this 
thesis (Branda and Dymecki, 2004;Kwan, 2002;Lewandoski, 2001;Nagy, 2000;Sorrell 
and Kolb, 2005;Thyagarajan et al., 2001). 
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1.4 The Cre/Lox System 
1.4.1 Overview of Function 
Cre/lox is a site-directed bacterial recombination system that enables DNA sequence 
modifications to be restricted to particular cell types and times of onset (Lewandoski, 
2001;Nagy, 2000). Cre (“causes recombination”) derives from phage P1 and belongs 
to the integrase family of site-specific DNA recombinases. Without the need for 
additional co-factors, cre recombinase catalyzes recombination between two of its 
recognition sites termed loxP sites (“locus of crossing over”). The enzyme recognizes 
the 34-bp loxP site (Hamilton and Abremski, 1984) by binding to its 13-bp inverted 
repeat elements that flank an 8-bp asymmetric core sequence (see figure I3).  
 
 
 
Besides the classic loxP sites, several other cre recognition sequences have been 
identified (e.g. lox511, lox71) that are functionally similar to loxP (Langer et al., 
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2002;Soukharev et al., 1999). The loxP core sequence is not involved in cre binding, 
but is the site of crossing over and provides directionality by its asymmetrical nature. 
Although cre-mediated recombination between two loxP sites in the same orientation 
is essentially a reversible process, it will effectively result in the deletion of the 
intervening sequence due to the loss of the circular reaction product (see figure I3). 
The binary cre/lox system therefore allows genetic manipulation with spatial precision 
as a recombination event can only take place in cells where both, cre protein and cre 
targeting sequences, are present. This robust, binary DNA recombination system has 
thus far been utilized in a variety of species, tissues and cell-types. The recent report 
on successful cre-mediated recombination in human embryonic stem cells 
furthermore points to a possible role in future gene-therapy approaches (Nolden et 
al., 2006). 
 
1.4.2 Applications in Mouse 
Originally applied to the mouse by Orban and colleagues (Orban et al., 1992) the 
cre/lox system initially found widespread use for the removal of selectable marker 
cassettes in classical knock-out strategies. These selectable marker cassettes 
influence the expression of genes at distances even greater than 100 kb (Pham et 
al., 1996). Meanwhile, the cre/lox system has also been successfully used to address 
a vast variety of other questions in mice including the effects of conditional gene 
inactivation (Gu et al., 1994) or gene over-expression (Lakso et al., 1992) and 
genomic rearrangement (Yu and Bradley, 2001). Recently, the cre/lox system was  
furthermore combined with the shRNA approach to generate inducible reductions of 
gene expression in mice (Yu and McMahon, 2006). 
 
To achieve conditional gene inactivation by the cre/lox system in the mouse, an 
essential part of the gene of interest is loxP flanked (“floxed”) by gene targeting, 
ideally leaving the gene expression before cre-mediated recombination at wild-type 
level. The mouse line carrying the floxed allele is then interbred with a “cre-provider” 
line, i.e. a mouse line that was separately engineered to show a defined cre 
recombinase activity pattern. In their offspring, the floxed allele will be excised in the 
cells where cre recombinase is active (Nagy, 2000). Crossing one mouse line with a 
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floxed gene of interest to various cre lines with different activity profiles therefore 
elegantly allows to independently study the diverse functions of a single gene in 
multiple tissues. Conveniently, the activity and expression profiles of a large number 
of currently available cre lines are accessible through the online database at 
http://nagy.mshri.on.ca/PubLinks/indexmain.php (Nagy and Mar, 2001). 
 
Using this approach, our group revealed the function of CRHR1 in limbic brain 
structures by generating a mouse line in which the CRHR1 gene was selectively 
disrupted in the anterior forebrain including the amygdala and striatum. For this 
purpose, mice were generated in which exons 9-13 of the CRHR1 were flanked by 
loxP sites and crossed with mice expressing cre recombinase under the control of 
the Camk2a promoter (Casanova et al., 2001). In this case, cre expression and 
subsequent CRHR1 deletion is restricted to the above-mentioned brain structures. As 
the pituitary gland is exempt from CRHR1 deletion, it could be shown that CRHR1 
modulates anxiety-related behavior independent of HPA axis function (Muller et al., 
2003). 
 
1.4.3 Cell-type Specific Cre Expression 
To provide cell-type specifity to cre recombinase as in the above-mentioned example 
of the forebrain specific Camk2a cre line, cell-type specific promoters are used to 
drive cre expression. However, adequate and well-defined, already-cloned promoters 
that would guarantee the desired expression pattern are not available for all cell-
types. This problem can be circumvented using a knock-in strategy as in this thesis. 
The cre recombinase open reading frame (ORF) for this purpose replaces the ORF 
of an endogenous gene. For adrenocortical specificity, the endogenous gene 
encoding the receptor for adrenocorticotropic hormone (ACTHR) was chosen. As 
only the ORF of an endogenous gene is precisely replaced, all regulatory elements, 
such as promoter, enhancer and silencer elements, that normally restrict the 
expression of the endogenous gene to a certain cell-type will be left fully functional. 
Expression of an inserted, exogenous gene is therefore thought to mimic the 
expression of the endogenous gene.  
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A second way to ensure the presence of all regulatory sequence elements that are 
required for a cell-type specific expression of an exogenous gene is the use of large 
DNA vectors (e.g. BACs, cosmids etc.) as expression cassettes. This strategy was 
pursued in the second part of the thesis with the generation of a ACTHRcre cosmid 
construct. BACs (and cosmids) carrying most sequences of interests are readily 
available and can be used either for transgene generation via microinjection or for 
gene targeting in mouse ES cells (Liu et al., 2003). An additional benefit of BAC 
transgenes is that they are less prone to effects of chromosomal integration site on 
the levels of transgene expression, so called position effects. This is most likely due 
to the size of flanking DNA which is much larger than in traditional transgene 
constructs (Branda and Dymecki, 2004;Copeland et al., 2001;Heintz, 2001). 
 
1.4.4 Inducible Cre Expression 
While using the classical cre/lox system already permits cell-type specific genetic 
manipulations, the control over the temporal dimension of cre expression was added 
by the generation of inducible cre variants first reported by Kühn and colleagues in 
1995 (Kuhn et al., 1995). To this end, several design strategies have been pursued, 
most of which are based on the fusion of cre recombinase to a steroid receptor ligand 
binding domain (LBD). These strategies take advantage of the nuclear localization 
capability of steroid receptor LBDs when bound to their ligand. The cre-LBD fusion 
protein is translated in the endoplasmatic reticulum and will remain in the cytoplasm, 
since the LBD forms a complex with heat shock protein 90 (hsp90) which precludes 
translocation into the nucleus. After binding the ligand, the cre-LBD/hsp90 complex 
dissociates, enabling nuclear translocation of cre. Only then cre mediated DNA 
recombination can occur, as cre and target DNA are now located in the same 
subcellular compartment (see figure I4) (Lewandoski, 2001).  
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A particularly successful strategy to achieve inducibility exploits the mutated LBD of 
the estrogen receptor fused to the c-terminus of cre recombinase (Brocard et al., 
1997;Feil et al., 1996;Metzger et al., 1995;Schwenk et al., 1998). This mutated LBD 
does not bind endogenous steroids but synthetic ligands exclusively, lowering 
background activity induced by endogenous estrogen. CreERT2, first described by 
Feil and colleagues (Feil et al., 1997), is a cre recombinase fused to the human 
estrogen receptor LBD with three point-mutations (G400V/M543A/L544A). These 
point mutations render the LBD insensitive to estrogen binding, but allow a very high 
inducibility following tamoxifen administration even at comparatively low doses 
(Casanova et al., 2002;Feil et al., 1997). 
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For induction of recombination, tamoxifen, a selective estrogen receptor modulator 
widely used in the therapy of breast cancer (Jordan, 2003), can be administered 
either systemically or topically as shown by Vasioukhin and colleagues, who used 
tamoxifen-releasing dermal patches (Vasioukhin et al., 1999). Danielian and 
colleagues demonstrated that cre induction could also be achieved during embryonic 
development by tamoxifen administration to the mother (Danielian et al., 1998). The 
optimal amount and length of tamoxifen treatment for recombination induction varies 
depending on the cre line and the experimental question and has to be established 
specifically. Thus far, the CreERT2 variant has been expressed under a variety of 
tissue specific promoters resulting in specific expression in mouse skin (Indra et al., 
1999), smooth muscle (Kuhbandner et al., 2000), adipose tissue (Imai et al., 2001), 
bone (Kim et al., 2004), glia cells (Leone et al., 2003) (Mori et al., 2006) (Hirrlinger et 
al., 2006) and melanocytes (Yajima et al., 2006). 
 
1.4.5 Pitfalls of the Cre/Lox System 
A number of inherent limitations have to be taken into consideration when using the 
cre/loxP system in the mouse. First of all, cre mediated deletion will not lead to a 
rapid onset phenotype as the cre sequence needs to be transcribed and translated. 
The resulting cre protein will excise the target sequence in a stochastic, time 
dependent manner and degradation of mRNA and protein of the target gene will 
require further time. However, as the recombination event is a once-for-all event, 
deletion frequency will accumulate over time (Nagy, 2000). This may result in 
decreased cell-type specificity of recombination over time as observed in the first 
brain-specific cre line, the CaMKIIα-cre line. Their cre activity was initially described 
to be specific for hippocampal CA1 cells but was later found to extend to additional 
forebrain regions (Fukaya et al., 2003;Tsien et al., 1996). A further point of note is 
that mosaic cre expression in various cells of the same tissue will result in a 
compound phenotype which will in part arise from cells in which recombination has 
taken place and in part from cells where cre is not active. This appears of particular 
importance in the case of secreted molecules like hormones (Lewandoski, 2001). 
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A major concern to the usefulness of inducible cre variants is the so-called 
“leakyness”, i.e. the cre background activity in the absence of the inducing molecule 
which could result in recombination at undesired timepoints. Unwanted nuclear 
translocation is hypothesized to be secondary to proteolytic cleavage of the LBD from 
the recombinase (Zhang et al., 1996) or secondary to alternative splicing of the cre-
LBD RNA (Wunderlich et al., 2001). The tamoxifen-inducible CreERT2 used in our 
strategy has a very favourable ratio of background activity to inducibility as compared 
to other inducible cre variants (Indra et al., 1999) including the codon-usage 
improved variants iCreERT2 and ERiCreER (Casanova et al., 2002). 
 
With respect to the loxP sites, several issues require attention: First, it is widely 
assumed that loxP flanked alleles exhibit wild-type expression levels of the floxed 
gene (Nagy, 2000). Xu and colleagues however reported a 70% reduction of floxed 
TrkB expression as compared to wildtype mice levels in the absence of cre 
recombinase (Xu et al., 2000). Furthermore, recombination frequency may be 
influenced by the position of the floxed locus within the genome (Vooijs et al., 2001). 
Concerns also arise from the existence of endogenous pseudo-loxP, i.e. degenerate 
loxP sites, that have been found in various genomes including the mouse genome 
(Thyagarajan et al., 2000). Consequently, DNA damage through recombination 
between pseudo-loxP sites has been observed in cultured mouse cells when cre was 
expressed at high levels (Loonstra et al., 2001). Furthermore, infertility of male mice 
due to cre expression in spermatids has been demonstrated for the same reason 
(Schmidt et al., 2000). However, even in the light of the above-mentioned limitations, 
the general robustness and feasibility of the cre/loxP system for mouse genetics can 
be clearly deduced from the multitude of reports on its use in a variety of tissues 
including peripheral organs and the brain (Morozov et al., 2003). How the cre/lox 
system is applied for use in the mouse adrenal cortex will be described in the 
following section. 
 
1.5 Applying the Cre/Lox System to the Adrenal Cortex 
Thus far, neither a constitutively active nor an inducible cre mouse line have been 
reported that would specifically be feasible for DNA recombination in the adrenal 
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cortex. There are, however, several examples of cre lines originally designed for 
specificity to other tissues that exhibit activity in the adrenal gland such as the αGSU-
cre (Cushman et al., 2000), the TH-cre (Lindeberg et al., 2004), the PSA-cre (Ma et 
al., 2005) and the INHA-iCre (Jorgez et al., 2006). All of these lines though, do not 
express cre in the adrenal cortex but in the adrenal medulla. Alternatively, expression 
in the adrenal cortex is extremely low and cursory, while expression in other tissues 
is high. A truly “adrenocortical” cre mouse line therefore would be complementary to 
the lines yet in existence and allow for the reliable and independent dissection of 
adrenal gene function in its two major compartments, cortex and medulla. How cre 
expression can be restricted to the adrenal cortex will be outlined in the following 
section. 
 
1.5.1 The Receptor for Adrenocorticotropic Hormone 
In the experimental design presented in this work, cre expression is restricted to 
adrenocortical cells by the endogenous regulatory elements of the receptor for 
adrenocorticotropic hormone (ACTHR), also termed melanocortin 2 receptor (MC2R). 
The murine ACTHR coding gene is located on chromosome 18, 37.0 cM in a 
genomic region that shows high inter-species conservation (Schioth et al., 
2003;Schioth et al., 2005). The 296 amino acids of the receptor protein are 89% 
identical to the human sequence (Kubo et al., 1995). The receptor is a G-protein 
coupled, seven transmembrane domains receptor and forms part of the melanocortin 
receptor family. The ACTHR is unique for its exclusive binding of ACTH and its lack 
of affinity to the other endogenous, agonistic or antagonistic ligands of the 
melancortic system such as α-melanocyte-stimulating hormone (αMSH), agouti 
signalling protein and agouti-related peptide (Abdel-Malek, 2001). Of the four other 
members of the receptor family, MC1R is involved in skin and hair pigmentation, 
MC3R and MC4R in energy homeostasis and MC5R in sebaceous gland secretion 
and pheromone release (Butler and Cone, 2002). 
 
The ACTHR is involved in the transduction of the ACTH signal to various second 
messenger systems including adenylate cyclase, protein kinases A and C and 
lipooxygenase (Beuschlein et al., 2001). ACTHR stimulation ultimately results in a 
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variety of effects including increased glucocorticoid release from the adrenal cortex. 
The ACTHR was also identified as the key molecule in transmitting the lipolytic action 
of ACTH in mammalian adipose tissue (Abdel-Malek, 2001). A directly proliferative 
activity in adrenal tumor formation of ACTH through ACTHR has been questioned 
(Rocha et al., 2003). However, the receptor is thought to play a role in the 
maintenance of the highly differentiated adrenal phenotype (Beuschlein et al., 2001). 
In humans, mutations in the ACTHR are causative for the familial glucocorticoid 
deficiency syndrome type 1, characterized by low levels of plasma cortisol despite 
high levels of plasma ACTH, which clinically presents as Addison’s syndrome (Clark 
et al., 1993).  
 
The gene encoding the murine ACTHR was first cloned and expressed in 1995 
(Cammas et al., 1995;Kubo et al., 1995). It spans approximately 23 kb and is 
organized in four exons, of which the first three encode the 5’ untranslated region (5’-
UTR). The fourth exon encodes part of the 5’-UTR and the entire protein coding and 
3’ untranslated regions. The second exon is alternatively spliced, resulting in two 
different mRNAs, one with and one without the 57-bp second exon (Shimizu et al., 
1997). More recently, an alternative first exon was discovered that encodes part of an 
alternative 5’-UTR and is solely expressed in adipose tissue (Kubo et al., 2004) (see 
figure I5). 
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1.5.2 Properties of the ACTHR Promoter 
Cammas and colleagues characterized the ACTHR promoter by showing that a 1,8 
kb sequence upstream of the transcriptional start site of the ACTHR restricted 
luciferase expression to Y1 adrenocortical cells in a cell culture assay. Promoter 
activity was conserved for increasing deletions of up to position 113 upstream of the 
transcription start site. However, a fragment of 900 bp upstream of the transcription 
start site did not effectively restrict reporter expression to adrenal cells any longer but 
enabled transcription in TM3 Leydig cells. Furthermore, the authors identified 
transcription factor binding sites for steroidogenic-factor 1 (SF1), one for octamer 
binding transcription factor (OctB), a glucocorticoid response element (GRE) and one 
binding site for each activating protein 1 and 2 (AP1 and AP2). By mutating one of 
the SF1-like binding sites the authors also showed that promoter specificity for the 
adrenal is at least in part mediated by SF1. A negative control element of so far 
unknown characteristics precludes ACTHR expression in other SF1 expressing 
tissues and is situated between 1200 bp and 900 bp upstream of the transcriptional 
start site. The presence of the GRE is hypothesized by the authors to play a role in 
glucocorticoid-mediated downregulation of ACTHR expression (Cammas et al., 
1997). Zwermann and colleagues were able to show that DAX-1 (“dosage-sensitive 
sex revearsal, adrenal hypoplasia congenita, critical region on the X-chromosome, 
gene-1”) is involved in providing adrenal specificity to ACTHR expression (Zwermann 
et al., 2005). Most recently, the presence and functional relevance of pre-B-cell 
transcription factor 1 (Pbx1) binding sites has also been demonstrated (Lichtenauer 
et al., 2007). ACTHR expression in adipose tissue is regulated via a peroxisome 
proliferator-response element (Noon et al., 2004). A stimulatory effect of the G-
protein subunits Gβ and Gγ on ACTHR expression could also be demonstrated (Qiu 
et al., 1998). Notably, the ACTHR mRNA is upregulated following stimulation by its 
own ligand ACTH in cultured human and mouse adrenocortical cells (Mountjoy et al., 
1994). 
 
In the adult animal, the activity of the murine ACTHR promoter as evaluated by RT-
PCR of ACTHR mRNA shows high expression of ACTHR in the adrenal cortex. No 
expression could be detected in spleen, testis, liver, lung, heart, brain and kidney 
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(Cammas et al., 1997). Low levels of ACTHR mRNA could however be found in 
adipose tissue (Boston and Cone, 1996) and more recently also in murine pancreatic 
islet cells (Al-Majed et al., 2004). Within the adrenal gland, the expression is 
strongest in the outer layers of the cortex, namely the zona glomerulosa and zona 
fasciculata with only a few ACTHR mRNA positive cells in the medulla and none in 
the capsula as demonstrated by in-situ hybridization (Xia and Wikberg, 1996) (see 
figure I6). 
 
 
 
In a recent publication, ACTHR expression during developmental days 11.5 to 18.5 
(E11.5 to E18.5) and in the adult animal was evaluated by immunohistochemistry. 
The ACTHR was actively expressed in a variety of tissues including adrenal gland 
(E13.5 into adulthood), testis (E13.5 to E18.5), genital ridge and ovary (E11.5 to 
E12.5 and E13.5 to E18.5 respectively), mesonephros (E11.5 to E12.5), 
metanephros (E12.5 to E18.5), lung (E11.5 to E14.5), brain and spinal cord (E11.5 to 
E13.5), choroid plexus (E13.5 into adulthood) and the dorsal root and trigeminal 
ganglia (E13.5 to E15.5). These findings imply a role for the ACTHR in the 
morphogenesis of tissues that were so far thought to be unaffected by ACTH 
signaling (Nimura et al., 2006). The ability of ACTH to stimulate testosterone 
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production in fetal and neonatal testes in the mouse further underlines the 
importance of ACTHR signaling during embryogenesis (O'Shaughnessy et al., 2003). 
The implications of this widespread expression of ACTHR during embryogenesis for 
the strategy of restricting cre activity to the adrenal cortex by the use of the ACTHR 
gene regulatory sequences will be commented on in the discussion section. 
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1.6 Aim of the Thesis 
In this thesis project, genetic constructs are engineered and applied to the mouse 
that aim for the generation of novel cre mouse lines with constitutive and inducible 
cre recombinase activity restricted to the adrenal cortex. Cre mice are versatile tools 
for studying gene function in a cell-type specific and temporally-controlled manner. 
Thus far, no cre mouse line has been reported that permits conditional mutagenesis 
specific for the adrenal cortex. 
 
In order to achieve adrenocortical specificity of cre expression, the “knock-in” of an 
inducible cre recombinase into the endogenous locus of the adrenocorticotropic 
hormone receptor (ACTHR) was performed initially. The resulting ACTHR-CE2 mice 
however did not show the desired cre expression. In a second approach, constructs 
for ACTHR cre cosmid transgenic mice were designed and generated. Both a 
constitutively active and a tamoxifen-inducible cre variant are used in this thesis. 
 
The resulting cre mice will allow a vast array of experiments on adrenal gene 
function, including experiments on adrenal morpho- and tumorigenesis and 
endocrinology. Interbred with the conditional CRHR 1 knock-out mice created in our 
group, they will help to elucidate the role of the intra-adrenal CRH system on 
hormone regulation. Adrenocortical cre mice will therefore reveal insights into the 
function of the adrenal gland, an organ at the nexus between somatic and psychiatric 
illness.
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2 Materials 
2.1 Buffers and Solutions  
Buffers and solutions were prepared using Millipore Q purified H2O. Reagents were 
purchased from Sigma, Roth or Merck unless indicated otherwise. 
2.1.1 Electrophoresis Buffers 
2.1.1.1 Buffers for DNA Electrophoresis 
TAE buffer:   4.84 g Tris  
1.142 ml acetic acid  
20 ml 0.5 M EDTA, pH 8.0 
800 ml  H2O  
adjust pH to 8.3 with acetic acid  
adjust volume to 1 l with H2O  
 
6x Loading buffer Orange: 1 g Orange G  
10 ml 2 M Tris/HCl, pH 7.5  
150 ml glycerol  
adjust volume to 1 l H2O  
 
6x Loading buffer Blue:  0.25 g bromophenol blue  
600 ml glycerol      
10 ml 2 M Tris/HCl, pH 7.5   
adjust volume to 1 l with H2O  
2.1.1.2 Buffers for RNA Electrophoresis 
10x Running buffer:  41.94 g MOPS  
4.1025 g sodium acetate  
20 ml 0.5 M EDTA, pH 8.0  
    adjust pH to 7.4 with 2 M NaOH  
adjust volume to 1 l with DEPC- H2O  
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Loading buffer:    0.0025 g bromophenol blue  
4 ml formamide   
2 ml formaldehyde 
2 ml 10 x Running buffer  
adjust volume to 10 ml with DEPC- H2O  
2.1.2 Buffers for Southern Blotting 
 Denaturation buffer:  100 ml 5 M NaOH 
300 ml 5 M NaCl 
adjust volume to 1 l with H2O 
 
Neutralization buffer:  250 ml  2 M Tris/HCl, pH 7.5  
300 ml 5 M NaCl  
10 ml 0.5 M EDTA, pH 8.0  
adjust volume to 1 l with H2O 
 
 20x SSC:   175.3 g NaCl 
    88.2 g sodium citrate 
    800 ml H2O 
adjust pH to 7.4 with 1 M HCl  
adjust volume to 1 l with H2O 
 
Washing buffer:  100 ml 20x SSC  
10 ml 10% SDS  
adjust volume to 1 l with H2O 
 
Lysis buffer:    5 ml 1 M Tris HCl, pH 8.0  
10 ml 0.5 M EDTA, pH 8.0     
1 ml  5 M NaCl  
12.5 ml 20% Sarcosyl  
adjust volume to 500 ml with H2O  
add 5% (20 mg/ml stock) proteinase K prior to use  
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Precipitation buffer:  0.15 ml 5 M NaCl 
10 ml 99% Ethanol  
2.1.3 Buffers and Media for Bacterial and Cell Culture 
LB medium:   10 g tryptone 
    5 g yeast extract 
    10 g NaCl 
    adjust pH to 7.0 with 5 N NaOH 
    adjust volume to 1000 ml 
    sterilize by autoclaving 
 
2x BBS:   1.1 g BES 
    1.6 g NaCl 
    0.02 g Na2HPO4 
adjust pH to 6.95 with 5 N NaOH  
adjust volume to 100 ml with H2O 
pass through 0.22 µm filter 
store 1 ml aliquots at –20 °C.  
 
Culture medium  500 ml Dulbecco’s Modified Eagle Medium, 
for ES cells:    high glucose, plus Na-Pyruvate (DMEM, Gibco) 
75 ml fetal calf serum (heat-inactivated, PAN Biotech)  
1 ml β-Mercaptoethanol 500 x (Sigma) 
5 ml glutamine (Gibco) 
90 µl leukaemia inhibitory factor (Chemicon) 
  
Culture medium  500 ml DMEM (Gibco) 
for feeder cells:   57 ml fetal calf serum (PAA) 
    5,7 ml glutamine (Gibco) 
    5,7 ml non-essential amino acids (Gibco) 
 
2x Freezing medium 5 ml fetal calf serum (Gibco) 
for ES and feeder cells:  3 ml DMEM (Gibco)  
2 ml DMSO 
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Culture medium  500 ml DMEM 
for Y1 cells:   55 ml fetal calf serum (PAA) 
    0,5 ml penicillin/streptomycin (10 µl/ml) 
2.2 Cell Lines  
 
The neomycin resistant embryonic mouse fibroblasts (EMFI) feeder cells and the 
TBV2 (129S6/SvEv/Tac) ES cells were provided by S. Bourier (GSF). The IDG 3.2 
murine hybrid ES cell line (129S6/SvEv/Tac x C57Bl/6) was obtained from R. Kühn 
(GSF). The Y1 mouse adrenocortical cell line was a gift of F. Beuschlein (University 
of Freiburg). 
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2.3 Oligonucleotide Sequences  
Oligonucleotides were ordered at MWG Biotech or Metabion and used as PCR or 
sequencing primers or for linker construction. For sequences consult table 2. 
 
Table 2: Oligonucleotide names and sequences 
Oligonucleotide Sequence 
3’vrfyin ggtaagttacatagcgaaatgc 
3’vrfyout cacttccatgaacagaatggg 
3'HAfw aagcttggcgcgccggatccttaattaaagatctctcgagtgatccctgctttgagtgttg 
3'HAinnen1 ttatgacacctggctgttgc 
3'HAinnen2 gaaggaacagccaaactacg 
3'HAinnen3 ctgttactagagacccaagc 
3'HAinnen4 ggactgatttccacaatagc 
3'HAinnen5 gatagatatttgcaagtagagc 
3'HAinnengap2 atatatcagtggaaaacaggc 
3'HAinnnengap1 ctattactacatgtagaatacg 
3'HArev gggcccgtttaaaccttaagtctttagtttgctgc 
3'HA-Start ggctggtaagggatatttgc 
3'Probe1 gatgctgcttgtacccacg 
3'Probe2 tcaaagctcatggtgcaagc 
5’HAss tgtttcattatcatctcatggc 
5’vrfyin gctccattattctcttgtagc 
5’vrfyout aattctaggtttccacacagc 
5'HACregap actgcatgttacgaattggc 
5'HACregap2 aagggccttggaagcagc 
5'HAfw aagcttgtttaaaccttaaggtctcatcggttcc 
5'HAinnen1 caggcaggcttgctggc 
5'HAinnen2 atttcagagagccccatgc 
5'HAinnen3 ctggcaaacatgccaggc 
5'HAinnen4 gtagttgagactacaggtgc 
5'HAinnen5 ccacattactcataagttggc 
5'HArev ggcgcgccgaattcgtcgacggccggccgacgtcgccatcttccag 
5'Probe1 aatctgtaaacaccatgggc 
5'Probe2 cgttattctagtaagtgaaagt 
ACEvrfyin gtaacccatatttgcctggc 
ACEvrfyout caccattgtccacttgtccc 
AMP-frt-Xho ctcgaggaagttcctatactttctagagaataggaacttcgagattatcaaaaaggatcttcac 
AMP-Pac ttaattaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagta
BamAs aactgactaacacagacacg 
BamSs ctagcagaagaagcaagagc 
CreAs acgtaacagggtgttataagc 
Cre-BamH1 ggatccgccgcataaccag 
Cre-Connect atgctgtttcactggttatgc 
CREE-Aat gacgtcgagccatctgctggagaca 
CREE-Fse ggccggcctcagactgtggcagggaaa 
Cre-End cctacccggtagaattagc 
CREM-c catggagcagaagctgatctctgaggaggacctgtagggccgg 
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Table 2 (continued): Oligonucleotide names and sequences  
Oligonucleotide Sequence 
CREM-ncneu ccctacaggtcctcctcagagatcagcttctgctccatgacgt 
CreOutw ctcatcactcgttgcatcg 
Crevrfyin gcaggcaaattttggtgtac 
Crevrfyout cgaacctcatcactcgttg 
EcoAs ctacatctctgggatgaagc 
EcoSs ctttcatcacacaaccaagc 
Exon4As acaatcggagttatttcttgc 
FRi-5 agaggtaaaaatggaggaaagg 
FRT-BamFs ggatccgctagcggccggccgagctcgaattcatcg 
FRT-mlu gcagacgcgtgttgatggc 
frtOutw ttcctcgagtgatccctgc 
fse-Prom atcgatggccggccatcgcctgcaggagcttgggcttgaacatcg 
HindAs gctgtaaataggcagtaagc 
HindSs gatccaaatctacaggtagc 
IVS-Aat gacgtcgaattcgctagcggccggccatgattacgccaagctgg 
IVS-Notfw gcggccgccatgattacgccaagctgg 
IVS-Notrv gcggccgcttacttgtacagctcgtcc 
IVS-Sal gtcgacttacttgtacagctcgtcc 
IVS-XbaRv tctagacttacttgtacagctcgtcc 
Mar-1 tgatttctgtaagtcaacggc 
Mar-2 ctggtcagaagaatcactgg 
Mar-Asgr gggcccaccggtgtcggcttgctgaaactcgta 
Mar-Bam ggatcctgatccctgctttgagtgttg 
Mar-Cre gtgtacggtcagtaaattggacattttttcctgctggccgtt 
Mar-fse ggccggccagctgccactgctaaccaca 
MC2R-Link1 cggccggccgtcgacgaattcggcgcgccggatccttaattaaagatctctcgagat 
MC2R-Link2 ctcgagagatctttaattaaggatccggcgcgccgaattcgtcgacggccggccgacgt 
PCR-AAH cgtttaaaccttaaggtttaaaca 
PCR-HAA agcttgtttaaaccttaaggtttaaacgggcc 
PmlLinker-1 P-ccgtttaaaccacgtgggccgg 
PmlLinker-2 P-cccacgtggtttaaacggccgg 
Pneo-Afl-Hind aagcttcttaaggaagttatcgaagttccta 
Pneo-Apa-Afl gggccccttaagttgtcttcccaatcctccc 
Pneo-Asc ggcgcgccgaagttatcgaagttccta 
Pneo-PacI ttaattaattgtcttcccaatcctccc 
pntflprsrsalgap agatgacaggagatcctgc 
pntflprsrsalgap2 cgtctcactagtctcgtgc 
post3'HA tgagtggtttgggcaagtg 
prAMP-Pac ttaattaaacccctatttgtttatttttct 
pre5'HA agactatacagtcagattgg 
Prom-mlu atcgatacgcgtgttgatggcaggggtacgaagccatattggctgcacggatcctg 
Rsr-FRT tatgtcctgatagcggtccg 
SrgSal-FRT caccggtgtagtgtcgacgaagttatcgaagttcctatt 
SV40-Asc gattaatttcaggcgcgcca 
SV40-Sal gtcgacatgataagatacattga 
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3 Methods 
For detailed protocols on molecular cloning, cell culture techniques etc. refer to 
Sambrook and Russell, 2001 (Sambrook and Russell, 2001). Updated versions of 
their protocols are available online at www.molecularcloning.com. 
3.1 Molecular Cloning Techniques 
3.1.1 Transformation of Plasmid DNA 
For transformation of plasmids into electrocompetent E. coli, 20 µl aliquots of cells 
(either MH1, DH5α or XL1-Blue) were thawed on wet ice and 20 ng of plasmid DNA 
was added. After incubation for 1 minute on wet ice, the mixture was transferred into 
pre-cooled electroporation cuvettes and an electric pulse was applied by a Gene 
Pulser Xcell (Biorad) following the manufacturer’s recommendations. Immediately 
after the pulse, 980 µl of 37 °C LB medium were added and the bacteria were shaked 
for 1 hour at 37 °C. 
 
For transformation of plasmid DNA into chemically competent E. coli, 100 µl aliquots 
of cells were thawed on wet ice for 15 minutes. Up to 5 µl (100 ng) of plasmid DNA 
were added and the mixture was incubated on wet ice for 15 minutes, followed by a 
45 seconds/42 °C heat shock. After 2 minutes on wet ice, 900 µl of LB medium (37 
°C) were added. The bacteria were then allowed to recover for 60 minutes under 
continuous shaking at 37 °C. 
 
After the recovery phase of both transformation procedures, a suitable volume of the 
transformation (usually 100 µl) was plated to LB-agar dishes containing either 
ampicillin (100 µg/ml) or kanamycin (30 µg/ml) and grown overnight at 37°C. Where 
applicable, LB-agar dishes were additionally plated with 40 µl of a 40 mg/ml X-Gal 
(Genaxxon) solution for blue-white selection. Subsequent screening of colonies was 
performed either by restriction digestion, colony lifting or colony PCR. Colony 
masterplates were stored at 4°C. Storage of clones for longer than 2 months was 
carried out in glycerol stocks of 250 µl E. coli culture and 750 µl autoclaved 80% 
glycerol at –80 °C. 
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3.1.2 Isolation of Nucleic Acids 
3.1.2.1 Isolation of Vector DNA 
For isolation of plasmid DNA, E. coli cells containing the respective plasmid were 
grown overnight at 37 °C in autoclaved LB-medium containing antibiotics, usually 
either ampicillin (100 µg/ml) or kanamycin (30 µg/ml). Plasmid DNA preparation was 
carried out by means of Qiagen Mini-/Midi-/Maxi-Prep kits according to the 
manufacturer’s protocols. DNA was eluted in sterile water and stored at –20 °C. 
 
For isolation of BAC and cosmid DNA, E. coli cells containing the respective BAC or 
cosmid were grown overnight at 37 °C in autoclaved LB-medium containing 
chloramphenicol (20 µg/ml). BAC and cosmid DNA was prepared using the Qiagen 
Large-Construct kit according to the manufacturer’s instructions. DNA was eluted in 
sterile water and stored at –20 °C. 
3.1.2.2 Isolation of Genomic DNA 
For preparation of murine tail DNA, tail tips of 0,5 cm length were cut from adult mice. 
Tails were either stored at –20 °C or used directly for DNA preparation by Promega 
Wizard Genomic DNA Purification kit following the manufacturer’s instructions. 
Genomic DNA from mouse tails was stored at 4 °C. 
 
To prepare genomic DNA from mouse liver, mouse liver avoiding the gallbladder was 
preparated and homogenized in a liquid nitrogen cooled mortar. The resulting tissue 
powder was resuspended in 1 ml NET buffer (100 mM NaCl; 25 mM EDTA; 2 mM 
Tris pH=7,5) per 0,1 g tissue. 1/10 volume 10% SDS and 1/10 volume 10 mg/ml 
proteinase k solution were added and incubated overnight at 56°C. The DNA was 
purified by phenol-chloroform extraction, ethanol-precipitated, solved in 1-2 ml of 
sterile water and stored at 4 °C. 
 
For extraction of genomic DNA from murine embryonic stem cells, an ES cell pellet of 
a confluent 9 cm cell culture plate was resuspended in 1 ml NET buffer (100 mM 
NaCl; 25 mM EDTA; 2 mM Tris pH=7,5). 100 µl of proteinase K solution (10 mg/ml) 
was added. After mixing and addition of 100 µl of 10% SDS the preparation was 
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incubated overnight at 56°C. The DNA was purified by phenol-chloroform extraction, 
ethanol-precipitated, solved in 0,5-1 ml of sterile water and stored at 4 °C. 
3.1.2.3 Isolation of Total RNA 
For preparation of total RNA from cultured cells, the cells were lysed directly on the 
culture dish with 1 ml of TRIzol (Invitrogen) per 10 cm2 of dish surface. After 
homogenization by pipetting, the lysate was transferred to a 50 ml tube and mixed 
vigorously. For separation of phases, the samples were incubated 5 minutes at room 
temperature before adding 0,2 ml of chloroform per 1 ml TRIzol (Invitrogen). The 
preparation was mixed again and incubated at room temperature and spun down in a 
table-top centrifuge at maximum speed at 4 °C for 15 minutes. The upper, aqueous 
phase was transferred into a new tube, mixed with 0,5 ml of isopropanol per 1 ml of 
TRIzol (Invitrogen) and incubated at room temperature for 10 minutes to precipitate 
the RNA. By centrifugation in a table-top centrifuge at maximum speed at 4 °C for 10 
minutes a RNA pellet was formed and the supernatant discarded. The pellet was 
washed with 1 ml 70% ethanol per 1 ml TRIzol (Invitrogen) reagent. After vortexing 
the mixture was centrifuged at 7500 g for 15 minutes at 4 °C. The supernatant was 
discarded and the RNA pellet dried for approximately 20 minutes at 37 °C and 
redissolved in a suitable amount of H2O (usually 40 µl). RNA concentration was 
measured by spectrophotometry and RNA quality was verified by agarose gel 
electrophoresis. 
3.1.3 Purification of DNA 
3.1.3.1 Phenol/Chloroform Extraction 
For purification, DNA was extracted from aequous solution by mixing the sample with 
an equal amount of phenol/chloroform/isoamylalcohol (25/24/1 parts). The resulting 
upper, aequous phase was carefully separated and mixed with an equal volume of 
chloroform/isoamylalcohol (24/1 parts). The upper phase was subsequently used for 
DNA recovery by ethanol precipitation. 
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3.1.3.2 Ethanol Precipitation 
For ethanol precipitation of DNA, the DNA sample was supplemented with 0,1 
sample volumes 3 M NaAcetate followed by 2,5 volumes of ice-cold 100% ethanol. 
After mixing, the DNA was precipitated for 10 minutes at –80 °C. The DNA was 
pelleted, washed with 70% ethanol, air-dryed and resuspended in the desired 
amount of H2O.  
3.1.3.3 PCR Purification 
Purification of plasmid DNA through binding to silica colums was performed after 
PCR or restriction digestion by means of the QiaPrep PCR Purification kit (Qiagen). 
3.1.4 Restriction Digestion of DNA 
Restriction digestion of plasmid DNA was performed as analytical or preparative 
digest. Analytical digestion was carried out for 1 hour at 37 °C with usually 500 ng of 
plasmid and 10 U of the respective restriction endonuclease. For preparative 
purposes, 5 µg of plasmid DNA were digested overnight with usually 50 U restriction 
endonuclease and restriction buffer, bovine serum albumine (BSA) and H2O 
according to the enzyme manufacturer’s protocols (New England Biolabs, MBI 
Fermentas, Roche or Gibco). Digestion of genomic DNA for Southern analysis was 
equally performed overnight at 37 °C with 10 µg of genomic DNA and 50 U restriction 
enzyme with supplementation of restriction buffers, BSA, spermidine and H2O as 
recommended by the enzyme manufacturer. Special attention was paid to possible 
star activity, methylation sensitivity and non-classical incubation temperatures of the 
enzymes. For SgrA I, the relaxation of restriction specifity after successful canonical 
restriction of its recognition site results in multiple undesired fragments following 
over-digestion (Bitinaite and Schildkraut, 2002). Therefore, the enzyme kinetics of 
SgrA I was estimated by stopping the restriction digest at different time points by 
adding 10-fold loading buffer and heating to 95 °C and the reaction conditions were 
optimized for the desired digestion. 
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3.1.5 Isolation of DNA Fragments 
For isolation, DNA fragments were routinely separated by agarose gel 
electrophoresis. The DNA band containing the desired fragment was identified using 
a UV transillumination table and excised using a disposable scalpel. Gel extraction 
was performed with the Qiagen QiaQuick Gel Extraction kit according to the 
manufacturer’s protocol. DNA was eluted in H2O, its concentration was determined 
and it was stored at –20 °C. In case of formation of single stranded DNA during 
purification, DNA was supplemented with NEB 10-fold restriction Buffer 3, heated to 
95 °C for 3 minutes and cooled down to room temperature. Thereafter DNA integrity 
was verified by gel electrophoresis. 
3.1.6 Ligation of DNA Fragments 
Standard ligation of DNA fragments was performed using T4 DNA Ligase (MBI 
Fermentas). To this end, 10 ng of vector backbone were mixed with a 3- to 10-fold 
molar excess of insert. H2O was added up to 17 µl and the mixture was heated to 70 
°C for 5 minutes to destroy tertiary structures that could potentially impair ligation 
efficiency. After 2 minutes on wet ice, 1 µl of T4 DNA Ligase and 2 µl of 10-fold 
ligation buffer were added. Ligation was routinely performed overnight at 16 °C 
followed by 15 minutes of heat inactivation at 65 °C. To decrease the formation of 
undesired plasmids during ligation, 1 µl of a feasible restriction endonuclease was 
added to ligations where possible. Non-standard ligations, i. e. ligations with 
fragments of unusual size, more than one insert, blunt-end overhangs etc. were 
performed as described above or using ligation kits, such as the Alligator (Genaxxon 
BioScience), Quick Ligation Kit (New England Biolabs) or Rapid DNA Ligation Kit 
(MBI Fermentas) according to the manufacturer’s protocols. 
 
To avoid religation of single-enzyme cut fragments, 5’ phosphate groups were 
removed when deemed necessary by either calf intestinal phosphatase (New 
England Biolabs) or shrimp alkaline phosphatase (Roche) according to the 
manufacturer’s recommendations. Advantage of the latter is that it can be heat-
inactivated by incubation at 65 °C rendering additional purification of DNA before 
subsequent ligation unnecessary. Integrity of the dephosphorylated fragment was 
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checked by T4 polynucleotide kinase (New England Biolabs) mediated re-
phosphorylation and subsequent use for ligation. 
3.1.7 Recombineering by Red/ET-Cloning 
The term recombineering refers to the modification of large DNA vectors like cosmids 
(or BACs etc. ) by homologous recombination (Copeland et al., 2001). The large size 
of these vectors generally requires their propagation in homologous recombination 
deficient strains of E. coli to prevent their rearrangement (Shizuya et al., 1992). 
Recombineering involves the restoration of the homologous recombination potential 
for a defined period of time while a DNA sequences to be inserted into the cosmid (or 
BAC etc.) is introduced into the bacteria. After the desired homologous 
recombination has occured the bacteria will ideally again lose their capacity for 
homologous recombination in order to preclude subsequent undesired recombination 
events. This aim can be achieved by the regulated expression of the homologous 
recombination proteins RecE/RecT from the Rac prophage (Zhang et al., 1998b) and 
the Redα/Redβ proteins from the lambda phage (Muyrers et al., 1999). In accordance 
with the utilized recombination pathways, the methods were termed “ET” or “Red” 
recombination. A combination of these methods called Red/ET-cloning is patented 
and marketed by Genebridges. 
 
In this thesis, a modified protocol based on the Counter-selection BAC Modification-
Kit protocol provided by the manufacturer (Genebridges) was used in order to 
integrate the targeting vectors pMC2RcreMYC and pMC2RcreERT2 into the cosmid 
MPMGc121E06653Q2 (purchased at RZPD, Berlin). In a first stage, the cosmid 
carrying E. coli clone was transformed with the Red/ET expression plasmid pSC101-
BAD-gbaA. To this end at least ten colonies carrying the cosmid were picked and 
they were used to inoculate a 1 ml overnight 37°C-culture in LB medium containing 
15 µg/ml kanamycin. The next day, 1.4 ml LB medium culture likewise containing 15 
µg/ml kanamycin was started with 30 µl of the overnight culture and grown for 2-3 h 
at 37 °C under constant shaking. To prepare cells for electroporation with pSC101-
BAD-gbaA they were pelleted by centrifugation at 4 °C and washed twice with 1 ml 
ice-cold H2O. After the supernatant was decanted, approximately 20 µl of cell 
suspension remained in the reaction vial to which 1 µl of pSC101-BAD-gbaA was 
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added. The cell suspension was then transferred to a pre-chilled 1 mm 
electroporation cuvette and electroporated at 1350 V, 10 µF, 600 Ohms. The cells 
were resuspended immediately after electroporation with 1 ml LB medium without 
antibiotics and grown at 30 °C for 70 minutes. The cells were then pelleted and 
resuspended in 100 µl LB medium and plated onto LB agar plates containing 15 
µg/ml kanamycin and 3 µg/ml tetracycline. The tetracycline containing plates were 
cast just prior to use and were kept light-protected in order to ensure tetracycline 
integrity. Plates were incubated overnight at 30 °C and subsequently stored at 4 °C.  
 
In a second stage, homologous recombination competent, electrocompetent cells 
were prepared from the E. coli strain generated in the first stage, that contain both 
the Red/ET expression plasmid pSC101-BAD-gbaA and the target cosmid 
MPMGc121E06653Q2. To this end, a 1 ml LB medium culture containing 15 µg/ml 
kanamycin and 3 µg/ml tetracycline was inoculated with at least ten colonies from the 
bacterial strain generated as described above. Culture was performed overnight at 
30 °C under constant shaking. The following day, a 1.4 ml LB medium culture 
containing the same antibiotics was started with 30 µl of the overnight culture and 
grown at 30 °C to an OD600 of 0.2. Subsequently, recombination capacity was 
induced by adding 20 µl L-arabinose 10% to the culture and growing the culture for 1 
h at 37 °C up to an OD600 of 0.4. For control purposes, parallel cultures were left 
uninduced. The bacterial cultures were then pelleted by centrifugation and washed 
twice in ice-cold H2O. Electroporation was carried out according to the principles 
described in the first stage, this time with the Pme I- linearized targeting vectors 
pMC2RcreMYC and pMC2RcreERT2, respectively. After recovery, cells were plated 
on LB agar plates containing 15 µg/ml kanamycin and 50 µg/ml ampicillin and 
incubated overnight at 37 °C. Control experiments were performed in parallel as 
described in the Counter-selection BAC Modification Kit protocol (Genebridges). 
3.1.8 Polymerase Chain Reaction 
3.1.8.1 Standard PCR 
Standard polymerase chain reaction (PCR) amplification of DNA was performed 
using Taq polymerase. After initial DNA denaturation for 7 minutes at 94 °C, 35 
cycles of denaturation (94 °C for 30 seconds), annealing (30 seconds) and 
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elongation were routinely carried out. The annealing temperature was chosen 
depending on the primer melting temperature as provided by the primer manufacturer 
and usually fell into the range of 50-65 °C. Time at 72 °C for elongation was chosen 
depending on the length of the supposed PCR product, with 1kb elongation 
estimated to require 1 minute. A final elongation step of 7 minutes at 72 °C followed 
the 35 cycles. For 100 µl of PCR mix, 20 pmol of each primer were used. In case of 
plasmids, 20 ng of template DNA were used, in case of genomic or BAC DNA about 
100 ng. Taq polymerase, desoxynucleotide triphosphates (dNTPs), PCR buffers, 
MgCl2 and H2O were added as described by the Taq polymerase manufacturer 
(Abgene, Roche). 
 
PCR products were commonly subcloned into pCRII-TOPO vectors (Invitrogen), 
exploiting the characteristic property of Taq polymerase to add A-overhangs to the 5’ 
end of synthezised strands. To control for the introduction of mutations by the 
inherently error-prone PCR, subcloned PCR products were sent for commercial 
sequencing (Sequiserve). 
3.1.8.2 PCR Amplification of Long DNA Fragments 
PCR using Taq polymerase becomes ineffective and error-prone in case the length 
of the desired PCR product exceeds 2kb. For generation of longer PCR products the 
Expand Long Template PCR System (Roche) or Herculase polymerase (Stratagene) 
that are based on DNA polymerases with proof-reading activity or mixtures of DNA 
polymerases were used following the manufacturers’ protocols. 
3.1.8.3 Nested PCR 
Nested PCR allows the amplification of templates that are present only in very low 
amounts. In a first step, a standard PCR is run on the desired template with a specific 
primer pair. The product of this first PCR is subsequently used as template for a 
second PCR with “nested” primers, i. e. primers that are located in between the 
primers of the first PCR. 
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3.1.8.4 Multiplex PCR 
Multiplex PCR utilizes more than two specific primers on a given template. Different 
primer pairs resulting in different PCR products therefore allow the differentiation 
between template sequence configurations in a single PCR. Multiplex PCR is 
typically applied for genotyping. 
3.1.8.5 Megaprime PCR 
Megaprime PCR allows the ligation of overlapping DNA fragments, i. e. one typically 
very large “primer” and a “template” strand. The initial denaturation step of the PCR 
results in single stranded DNAs that bind as PCR primers to the complementary 
overlap on a strand from the ligation partner. Megaprime PCR efficiency is usually 
enhanced by combining it with a multiplex PCR approach by adding the 5’ primer of 
the 5’ fragment and the 3’ primer of the 3’ fragment (compare figure R4). 
3.1.8.6 Colony PCR 
Colony PCR was used to identify bacterial clones that comprise a desired plasmid. 
To this end, bacterial colonies are picked and transferred to PCR tubes containing 50 
µl of H2O. These probes are heated to 95 °C for 15 minutes to crack the bacteria. 
After cooling down, 5 µl of the probes are used as PCR templates with primers that 
allow the identification of the desired plasmid. 
3.1.8.7 Reverse Transcription PCR 
To generate cDNA templates for subsequent PCR, reverse transcription was 
performed using SuperScript II (Invitrogen) reverse transcriptase. 0,5 µg of total RNA 
were mixed with 1 µl (500 µg/ml) oligo dT primers (Amersham), supplemented with 
H2O up to 11 µl, haeted to 70 °C for 5 minutes and put on wet ice for 1 minute. 4 µl of 
5x First Strand Buffer (Invitrogen), 2 µl 0,1 M DTT, 1 µl 10 mM dNTP, 1 µl 40U/µl 
RNasin (Promega) and SuperScript II (Invitrogen) reverse transcriptase were added 
and the mix was heated first to 42 °C for 60 minutes, then to 70 °C for 15 minutes. 
After reverse transcription, RNA was destroyed by addition of 2 U/µl RNase H 
(Invitrogen) and 20 minutes incubation at 37 °C followed by 15 minutes heat 
inactivation at 70 °C. The resulting first strand cDNA served as template for the 
following PCR. 
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3.1.8.8 Primer Design 
PCR primers were designed manually according to the following principles: The 
primer length should be around 20bp and G/C content about 50%. The melting 
temperature was designed to be around 58 °C with nucleotides A or T calculated to 
contribute 2 °C and G or C to contribute 4 °C. Additional nucleotides were added to 
the priming sequences as needed for restriction sites etc. To avoid the positioning of 
primers into repetitive sequences, oligonucleotides were analyzed in silico using 
Primer3 and Repeatmasker software when deemed necessary. Primers were 
ordered at MWG Biotech or Metabion. 
 
3.1.9 Agarose Gel Electrophoresis 
Gel electrophoresis for separation of DNA fragments in the range of 100bp to 20kb 
was performed on agarose gels (Ultra Pure Agarose, Invitrogen) in 1x TAE buffer. 
Agarose concentration was adjusted within the range of 0,7-2,0% according to the 
desired separation optimum. Gel running time and voltage were adjusted likewise 
according to the desired separation characteristics.  
 
For quality control of RNA preparations, 1,5% agarose gels were loaded with a RNA 
aliquot to be tested that was heated to 65 °C with RNA Loading Buffer. 
 
Staining of nucleic acids was achieved by the intercalating fluorescent dye ethidium 
bromide which was added to a final concentration of 0,5 µg/ml to the the agarose gel 
before solidification. For determination of DNA fragment size the 1kb Plus DNA 
Ladder (Invitrogen) was used. Stained nucleic acids were visualized on a UV-
transilluminator and photographed. 
3.1.10 Determination of DNA/RNA Concentration 
DNA and RNA concentrations between 100 ng/µl and 1 µg/µl were determined by 
UV-spectrophotometry at 260 nm following the equation c[µg/ml]=OD260 x V x F. 
OD260 denominates the optical density measured at 260 nm, V the factor of dilution. 
Differences in extinction between DNA and RNA are accounted for by F, which is 50 
for dsDNA and 40 for RNA. DNA concentrations of less than about 100 ng/µl were 
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determined by gel electrophoretic comparison to the SmartLadder (Eurogentec) 
weight standard. 
 
3.2 Blotting Techniques 
3.2.1 Southern Blotting of Agarose Gels 
Southern blotting was used to transfer DNA from agarose gels onto nylon 
membranes for subsequent hybridization with specific probes. DNA separation by 
agarose gel electrophoresis was executed at low voltage overnight (e.g. 40 V for 12-
16 h) to ensure sufficient fragment separation. DNA was denatured by bathing the 
gel twice for 15 min in denaturation buffer followed by twice 15 minutes in 
neutralization buffer and equilibration for at least 10 min in 20 x SSC.  
 
The nylon blotting membrane (Hybond N, Amersham) and Whatman 3 mm filter 
paper were pre-wet in 20 x SSC. The agarose gel to be blotted was put onto the 
Whatman 3 mm filter paper, which had contact to a reservoir containing 20 x SSC. 
On top of the gel, the nylon membrane was located followed by two additional layers 
of Whatman paper and a stack of cellulose tissue for absorption of the 20 x SSC 
transfer liquid and a 1 kg weight. Any air bubbles between the gel, the membrane 
and Whatman 3 mm papers were carefully removed. The gel was blotted overnight 
(12-16 h, not more than 24 h) and UV crosslinked (UV Stratalinker® 2400; 
Stratagene).  
 
25-50 ng of DNA probe were labelled with 50 µCi α-32P-dCTP (Amersham) by the 
random hexamer-primers based Megaprime DNA Labelling kit (Amersham) 
according to the manufacturer’s instructions. The labelled probe was purified from 
free nucleotides by MicroSpin S-300 HR columns (Pharmacia). Efficiency of labelling 
was checked by scintillation counting on a gamma-counter. Pre-hybridization of the 
blotting membranes was carried out at 65 °C for 30 min in Rapid-Hyb Buffer 
(Amersham). After denaturation of radiolabelled DNA probes at 95 °C for 5 min, 
hybridization was carried out for 2-3 h at 65 °C in Rapid-Hyb Buffer (Amersham). The 
membranes were then washed once in 2 x SSC, 0.1 % SDS for 20 min and twice in 
0.2 x SSC, 0.1 % SDS for 15 min at 65 °C. Membranes were exposed for suitable 
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periods of time (usually 1-2 days) to phospho-imaging screens or to X-ray films 
(Kodak). For hybridization with additional probes, membranes were stripped of 
probes by boiling in 0.1 % SDS for 20 minutes followed by rinsing with 2x SSC. 
3.2.2 Colony Hybridization 
To identify clones with a specific plasmid 
amongst a large number of E. coli colonies, 
colony hybridization (also: “colony lifting”) 
was performed. To this end, Hybond N 
nylon membranes (Amersham) were put 
onto agar plates with the E.coli colonies for 
transfer of colonies. The membranes were 
subsequently laid twice for 10 minutes 
facing up in denaturalization buffer and 
twice in neutralization buffer for 10 minutes, 
followed by 5 minutes in 2 x SSC for 5 min. 
After drying, membranes were UV 
crosslinked (UV Stratalinker® 2400; 
Stratagene) and used for hybridization. 
Generation of specific probes and 
hybridization were carried out as described 
for Southern blotting of agarose gels. 
Exposure time to X-ray films (Kodak) however was only 30 minutes to 2 h. 
3.3 Cell Culture Techniques 
3.3.1 Manipulation of Embryonic Stem Cells 
Murine embryonic stem cell lines (ES cells) were established independently by two 
groups in 1981 (Evans and Kaufman, 1981;Martin, 1981). They are pluripotential 
stem cell lines derived from the primitive ectoderm of the mouse blastocyst (Brook 
and Gardner, 1997). ES cells can be cultured and manipulated in vitro, during which 
time they remain undifferentiated and maintain their pluripotency. Once reintroduced 
into the environment of a blastocyst or a morula, the ES cells colonize the inner cell 
mass and give rise to all the different tissues of the resulting organism, including its 
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germ cells. A genetic modification introduced into the ES cell genome can thus be 
transmitted to subsequent generations (Capecchi, 2001). In order to maintain the 
pluripotency of the ES cells they are cultured on dishes plated with neomycin-
resistant embryonic mouse fibroblast (EMFI) feeder cells that secrete differentiation-
inhibiting factors into the culture medium. The culture medium is furthermore 
supplemented with leukaemia inhibitory factor (LIF) to aid maintenance of their 
undifferentiated state (Chambers, 2004). 
3.3.1.1 Culture of Embryonic Mouse Fibroblast Feeder Cells 
For preparation of feeder cells plates, a frozen vial of EMFI feeder cells was thawed 
quickly at 37 °C. Cells were transferred into a plastic tube containing 10 ml feeder 
cell culture medium and centrifuged. The cell pellet was resuspended gently in 10 ml 
feeder cell culture medium and cells were seeded onto 3 x 15 cm plates each 
containing a total of 25 ml feeder cell culture medium. Incubation was performed at 
37 °C, 5 % CO2 for 3 days after which the medium was removed and 15 ml feeder 
cell culture medium containing 150 µl mitomycin C (MMC) (1 mg/ml) was added in 
order to mitotically inactive the feeder cells. Plates were swirled to ensure an even 
distribution of the medium and cells were incubated at 37 °C, 5 % CO2 for exactly 2.5 
h. One culture plate of feeder cells was usually left without MMC treatment in order to 
maintain a stock culture for subsequent generation of feeder plates.  
 
For trypsinization, the cell monolayer was washed twice with 10 ml phosphate 
buffered saline (PBS, Gibco) and 7.5 ml trypsin/EDTA (Gibco) were added to each 
plate. Plates were then incubated for about 5 min at 37 °C and the resulting cell 
suspension was pipetted up and down for 3 times to break cell aggregates. The 
resuspended EMFI cells were then transfered to a 50 ml plastic vial, containing at 
least the same amount of feeder cell culture medium as trypsin/EDTA used for 
trypsinization. The cells were pelleted by centrifugation and resuspended in feeder 
cell culture medium to a final concentration of 2.0 x 105 cells/ml. Mitotically 
inactivated feeder cells were immediately plated at a density of 104 cells/cm2 on 
dishes containing feeder cell culture medium. Feeder cells were allowed to attach 
overnight or for at least 3 h before medium change to ES cell medium and seeding of 
ES cells.  
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3.3.1.2 Culture of Embryonic Stem Cells 
 A vial of frozen IDG 3.2 ES cells was thawed quickly and transferred to a laboratory 
tube containing 10 ml ES cell medium 
without LIF for washing. The cell suspension 
was spun down by centrifugation and the 
pellet was resuspended in 5 ml ES cell 
medium containing LIF. Cells were plated 
onto a 6 cm- cell culture dish with EMFI cells 
and grown at 37 °C and 5% CO2. Medium 
change was performed daily. For splitting, 
cells were washed with PBS twice and 
incubated with 1.5 ml trypsin/EDTA for 10 
min at 37 °C, 5 % CO2, until the cells 
became detached. The cells were then 
gently pipetted up and down to obtain a 
single cell suspension after which 10 ml of 
ES cell medium without LIF were added. 
Following centrifugation, the supernatant was 
aspirated and cells were resuspended in ES 
cell medium containing LIF. About 2 x 106 
cells per 10 cm diameter dish were plated to 10 cm feeder plates or, for freezing or 
electroporation, on plates coated with 0.1 % gelatine. 
3.3.1.3 Electroporation of Embryonic Stem Cells 
For electroporation with linearized vector DNA, an ES cell suspension of 7 x 106 cells 
per electroporation was made in 800 µl ice-cold PBS. 20 µg of the linearized 
targeting vector were added. The cell suspension was then transfered to the 
electroporation cuvette and electroporation was performed at 0.24 kV, 500 µF for 
approximately 6 ms on a Bio Rad Gene Pulser. After the pulse, the cells were 
incubated on wet-ice for 10 to 20 min. The cell suspension from the cuvette was then 
seeded onto two 10 cm feeder cells plates containing 9 ml ES cell medium each. 
Medium was changed daily. Two days after electroporation, selection with G418 
(geneticin, Life Technologies) was started at 200 µg/ml. Selection with 2 µM 
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ganciclovir was initiated on the fourth day after electroporation. Drug-resistant 
colonies were picked on the 12th day after electroporation and transferred into 96-well 
feeder cell coated plates. Selection was continued and clones were passaged to 
produce dublicate plates. Two duplicates on gelatine coated 96-well plates were 
used for screening by Southern blotting. Two duplicates on feeder cell coated 96-well 
plates were stored with freezing medium in liquid nitrogen for subsequent clone 
expansion after identifiation of homologously recombined clones.   
3.3.1.4 Identification of Homologously Recombined ES Cells 
 After growing to about 70% confluency, the ES cell clones on the gelatine coated 96-
well plates were rinsed twice with PBS and 50 µl lysis buffer per well were added. 
The plates were then incubated overnight at 50 °C and spun down the next day by 
centrifugation. To precipitate DNA, 100 µl of NaCl/ethanol (150 µl of 5 M NaCl in 10 
ml of Ethanol) were added per well. The 96-well plate was shaked for 30 min at room 
temperature and spun down again. Supernatants were discarded, carefully leaving 
the DNA pellets attached to the culture plate. The pellets were rinsed three times with 
150 µl of 75% Ethanol per well. After the final washing step, plates were allowed to 
dry on the bench.  
 
For restriction digestion, 30 µl of restriction digestion mix containing the appropiate 
restriction enzymes and buffers were added per well and the reaction was incubated 
overnight at 37 °C. Gel electrophoresis loading buffer was added to the samples and 
electrophoresis was performed. From the agarose gels, DNA was transferred to 
Nylon membranes by Southern blotting and hybridized with radioactively labelled 
probes as described earlier. 
3.3.1.5 Preparation of ES Cells for Blastocyst Injection 
For expansion of ES cell clones that were identified to exhibit the desired 
homologous recombination event, 96-well duplicate plates stored in liquid nitrogen 
were thawed in a waterbath at 37 °C. After centrifugation, the freezing medium was 
replaced by ES cell medium and the cells were transferred to a fresh 96-well feeder 
plate. Clones were subsequently expanded by splitting onto 24-well plates, followed 
by splitting to 6-well plates and 10 cm plates when sufficient confluency was reached. 
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For storage, expanded clones were trypsinized, medium was changed to freezing 
medium and clones were stored in liquid nitrogen. For blastocyst injection, vials 
containing the desired clones were thawed following the principles described earlier 
and plated onto 6 cm plates. The day before injection, cells were passaged to a 
gelatine coated 6 cm plate. 
3.3.2 Culture of Y1 Adrenocortical Cells 
For culture of Y1 adrenocortical cells (Rainey et al., 2004;Schimmer, 1979), a frozen 
vial of Y1 cells was thawed quickly at 37 °C. Cells were transferred into a plastic tube 
containing 10 ml Y1 cell culture medium and centrifuged. The cell pellet was 
resuspended gently in 10 ml Y1 cell culture medium and cells were seeded onto a 10 
cm dish. Incubation was performed at 37 °C, 5 % CO2 until 80 % confluency was 
reached. For splitting, the cell monolayer was washed twice with 10 ml phosphate 
buffered saline (PBS, Gibco) and 7.5 ml trypsin/EDTA (Gibco) were added to each 
plate. Plates were then incubated for about 5 min at 37 °C and the resulting cell 
suspension was pipetted up and down for 3 times to break cell aggregates. The 
resuspended Y1 cells were then transfered to a 50 ml plastic vial, containing at least 
the same amount of Y1 cell culture medium as trypsin/EDTA used for trypsinization. 
The cells were pelleted by centrifugation, resuspended in Y1 cell culture medium and 
plated in the desired densities. 
 
For transfection in 6-well plates, 600.000 – 700.000 Y1 cells per well were plated. 
Transfection was performed at a confluency of approximately 70%, which was 
typically reached 12 h after plating. Transfections were either performed by the 
Lipofectamine 2000 (Invitrogen) method according to the manufacturer’s protocol or 
using the calcium phosphate method. For every well to be transfected by the calcium 
phosphate method, 10 µl 2,5 M CaCl2 were added to 4 µg of DNA and the sample 
was filled up to 100 µl with H2O. After adding 100 µl of 2x BBS the sample was 
vortexed and incubated for 10 minutes at room temperature. The transfection mix 
was then pipetted dropwise into the well and after gentle rocking, the plate was 
incubated overnight at 37 °C and 5% CO2. The following day, medium was changed. 
In order to confirm transfection success visually, dsRed or eGFP expression 
plasmids were (co-) transfected and fluorescence was evaluated 24 h after 
transfection.
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4 Results 
4.1 Generation of Constructs pPNTflpCremyctagPml and 
pPNTflpCreERT2Pml 
In the following sections, the generation of constructs for gene targeting is described. 
These targeting constructs are engineered to allow the specific integration of 
sequences encoding either a constituitively active cre recombinase tagged with the 
human c-myc epitope (Evan et al., 1985) or the tamoxifen-inducible version 
CreERT2(Feil et al., 1997) into the murine ACTHR locus. For general strategies in 
gene targeting, construct design, clone screening etc. see Kwan et al., 2002 (Kwan, 
2002) and Joyner et al., 2000 (Joyner, 2000). The targeting constructs are then used 
for recombination in murine embryonic stem (ES) cells. Of recombinant ES cells, the 
mouse line ACTHR-CE2 was generated. 
4.1.1 Modification of the Universal Gene Targeting Vector pPNTflp 
The vector pPNTflp constructed by v. Waldenfels and Deussing in our group is a 
universal vector for gene targeting and combines the conditional gene targeting 
vector pPNT4 (Conrad et al., 2003) with a cassette self-excision strategy initially 
described in vector pRVa3ACN (Bunting et al., 1999). The vector pPNTflp contains the 
enhanced version of the Flp recombinase (FLPe) (Buchholz et al., 1998) under 
control of an angiotensin converting-enzyme promoter (ACE). This promoter is only 
active during spermatogenesis, resulting in expression of the controlled gene early 
during the formation of male germ-cells. A similar approach was taken by Bunting et 
al. who generated mice in which ACE promoter driven, cre recombinase mediated 
self-excision was achieved (Bunting et al., 1999). A neomycin resistance gene (Neo) 
expressed under the highly active phosphoglycerate kinase I promoter (PGK) is 
located upstream of the ACE-FLPe cassette. The neomycin resistance serves as 
positive selection marker for identification of ES cell clones with integration of the 
targeting construct. As the Neo maker was shown to influence expression of adjacent 
genes, it needs to be removed after the selection process (Pham et al., 1996). To this 
end, the vector region containing the Neo and Flp cassettes is flanked with frt sites, 
the recognition sites for Flp recombinase. Upon ACE promoter driven Flp expression 
during spermatogenesis, the entire region between the two frt sites will thus excise 
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itself (see figure R1) abolishing the neomycin selection cassette with its possibly 
detrimental effect on expression of neighbouring genes. 
 
 
 
The conditional gene targeting vector pPNT4 (Conrad et al., 2003) contributes a 
phosphoglycerate kinase I promoter driven thymidine kinase gene to vector pPNTflp. 
This cassette serves as negative selection marker for construct integration via 
homologous recombination: Thymidine kinase catalyzes the transformation of the 
non-toxic substance ganciclovir into a toxic metabolite thereby causing cell death. If 
integration into the host ES cell genome has occurred through homologous 
recombination, i.e. non-random, this cassette will be lost as it is designed to be 
located outside the homologous region in the final constructs. In contrast, ES cell 
clones with random construct integration will be killed upon ganciclovir 
administration. The loxP site in pPNTflp likewise originates from vector pPNT4 
(Conrad et al., 2003) and has to be eliminated in order to use this vector for 
generation of a cre knock-in, as it would serve as undesired cre recombinase target 
(see below). 
 
In order to linearize the final constructs for electroporation into ES cells, an additional  
Fse I restriction site was introduced into the pPNTflp vector. For this purpose, a PCR 
using primers FRT-Mlu and FRT-BamFs was performed on pPNTflp creating a 684 
bp replacement insert with a Fse I restriction site located 3’ of the BamH I restriction 
site. This fragment was subcloned, sequenced and ligated into pPNTflp using the 
Bam HI and Mlu I restriction sites. The resulting vector was sequenced for correct 
ligation and named pPNTflpfse (see figure R2). 
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To abolish the loxP site and to introduce additional Sal I and SgrA I restriction sites 
subsequently needed for cloning, a PCR was run on pPNTflp with primers Rsr-FRT 
and SrgSal-FRT resulting in  a 1260 bp product that was subcloned, sequenced and 
ligated into pPNTflpfse using the Xho I/Rsr II and Sal I/Rsr II restriction sites 
respectively (see figure R3). Sal I and Xho I have compatible overhangs that ligate to 
form a Taq I recognition site. The resulting vector was named pPNTflpfseSgr as 
through primer SrgSal-FRT a SgrA I restriction site was introduced upstream of the 
frt site. 
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4.1.2 Cloning of Homologous Arms 
4.1.2.1 Generation of the 5’ Homologous Arm 
The 5’ homologous arm (HA) was generated by long range PCR of murine C57BL/6J  
genomic DNA on the bacterial artificial chromosome pBACe3.6 RP23-179K16 
(obtained from F. Beuschlein, genetic strain background C57Bl6/J) using primers 
Mar-Asgr and Mar-Cre. The PCR product containing 2,8 kb homologous sequence 
including the ACTH receptor exon 3 as well as the 5’ terminus of the exon 4 up to the 
endogenous start codon was subcloned and sequenced. Through primer Mar-Asgr, 
Apa I and SgrA I restriction sites were added. Primer Mar-Cre created a 24 bp 
overlap to the 5’ terminus of the Cre-ORF allowing the 5’ HA to be used as primer in 
a megaprime PCR as described below. 
4.1.2.2 Fusion of 5’HA to Cre Recombinases 
Fusion of the 5’ homologous arm to the 5’ terminus of cre was achieved by 
combining a megaprime and multiplex PCR with megaprimer 5’HA and primers Cre-
BamH1 and Mar-Asgr using pCreERT2 (vector obtained from P. Chambon) as 
template (see figure R4). The PCR product was subcloned to form vector 
5’HACreTOPO and proven to comprise the 5’ HA fused to the first 361 bp of the 
CreERT2-ORF up to the endogenous BamH I restriction site by sequencing. 
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The resulting fusion product between the 5’HA and the cre 5’ terminus was ligated to 
the remaining 3’ terminal part of ORF of the tamoxifen-inducible CreERT2 using 
restriction sites Apa I and BamH I. The resulting vector 5’HACreERT2 was subcloned 
and insertion sites were sequenced (see figure R5). 
 
 
 
In an analogous way, fusion to the 3’ terminal part of the constitutively active 
nlsCremyctag (vector pnlsCremyctag obtained from K. Kobayashi) was achieved by 
ligation using the restriction sites Xba I/BamH I  and Spe I/BamH I respectively. Xba I 
and Spe I produce compatible cohesive overhangs that after ligation form a Bfa I 
recognition site. With the fusion to the 5’ terminus of the CreERT2, which was used 
as PCR template to create the fusion to the 5’HA (see above), the 5’ terminal nuclear 
localization signal (nls) of the nlsCremyctag was lost. The vector resulting from the 
ligation was termed 5’HACremyctag and correct ligation was verified by sequencing. 
4.1.2.3 Generation of the 3’ Homologous Arm 
The 3’ homologous arm was generated by long range PCR on pBACe3.6 (RP23-
179K16) using primers Mar-Bam und Mar-fse. The Mar-Bam primer adds a BamH I 
restriction site to the 5’ end of the 3’ homologous arm. The PCR product (expected 
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size 5,9 kb) was subcloned and sequenced. Sequencing failed for an 
adenine/guanine-rich region in the 3’ homologous arm which was therefore further 
characterized by nested PCR using primer pairs 3’HAinnen2/3’HAinnengap2 and 
FRi-5/3’HAinnengap1. The nested PCR revealed the respective region to be 
approximately 150 bp shorter in pBACe3.6 (RP23-179K16) as compared to the  
sequenced published online at www.ensembl.org. Nested PCR on pBACe3.6 (RP23-
179K16) DNA, genomic TBV2 (derived from strain 129S6/SvEv/Tac) and genomic 
C57Bl/6 DNA resulted in the same length of product, which therefore likely 
represents the true wild-type situation in these genetic backgrounds. In silico 
sequence analysis furthermore revealed an additional BamH I restriction site in the 
homologous arm, so that the final length of BamH I digest-recovered 3’ homologous 
sequence was 5,0 kb. 
4.1.3 Insertion of the 3’ Homologous Arm Into the Targeting Vector 
pPNTflpfseSgr 
The 5,0 kb of 3’ homologous sequence were recovered from the subcloning vector by 
BamH I digest and ligated into the BamH I linearized, dephosphorylated 
pPNTflpfseSgr vector. Clones with insertion of the 3’ HA were identified by colony 
PCR using primers FRi-5 and 3’HAinnengap1. Correct orientation of the 3’ HA was 
demonstrated by restriction digest and the resulting vector was named 
pPNTflpfseSgr3’HA (see figure R6). 
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4.1.4 Completion of the Targeting Constructs pPNTflpCremyctagPml and 
pPNTflpCreERT2Pml 
The CreERT2 targeting vector was completed by ligation of the 5’HA/CreERT2 
sequence into the SgrA I and Sal I restriction sites of vector pPNTflpfseSgr3’HA. 
Correct ligation was verified by sequencing of the insertion sites and the resulting 
vector was named pPNTflpCreERT2 (see figure R7). 
 
 
 
Analogously, the Cremyctag targeting vector was completed by ligation of the 
5’HA/Cremyc sequences of vector 5’HACremyctag into the SgrA I and Sal I 
restriction sites of pPNTflpfseSgr3’HA. The resulting vector was named 
pPNTflpCremyctag and verified by sequencing (see figure R8). 
 
 
 
Because of its low concentration of 2 U/µl, Fse I promoted linearization of the 
pPNTflpCreERT2 and pPNTflpCremyctag vectors required for electroporation into 
embryonic stem cells proved to be highly ineffective. To facilitate linearization, Pme I 
and Pml I restriction sites were inserted into the Fse I linearized, dephosphorylated 
targeting vectors through ligation with the hybridized linker oligonucleotides 
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PmlLinker-1 and PmlLinker-2. To anneal, both oligonucleotides were mixed, heated 
to 95°C and cooled down to room temperature. The resulting vectors were named 
pPNTflpCreERT2Pml and pPNTflpCremyctagPml (see figure R9), verified by 
restriction digest (see figure R10) and electroporated into murine IDG3.2 embryonic 
stem cells after Pml I mediated linearization. 
 
 
 
 
 
 
4.2 Embryonic Stem Cell Culture 
Murine IDG 3.2 hybrid (derived from strains C57Bl/6J and 129S6/SvEv/Tac) 
embryonic stem (ES) cells (obtained from R. Kühn) were cultivated on mitomycin C 
inactivated embryonic mouse fibroblast feeder-cells (EMFI). 7x106 ES cells (passage 
10) per cuvette were electroporated with 20 µg of Pml I linearized vector 
pPNTflpCreERT2Pml and pPNTflpCremyctagPml, respectively. Two days after 
electroporation, positive selection with G418 was initiated at a concentration of 180 
µg/ml. Four days after electroporation, G418 concentration was increased to 200 
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µg/ml. The same day, negative selection with 2 µM ganciclovir was started which was 
maintained until picking of clones (12 days post electroporation) or for half of the 
clones till the end of the in vitro manipulations. G418 selection was continued for 2 
additional days. Per construct, 192 clones were picked and transferred onto 96-well 
plates. Colonies were split according to their confluency after 2 days, and again after 
4 days, when duplicates of the clones were seeded on 96 well-gelatine coated plates 
for DNA extraction and subsequent Southern blot analysis.  
4.3 Screening of ES Cell Clones for Construct Integration 
In order to identify ES cell clones with the desired homologous recombination event, 
e.g. with knock-in of the CreERT2 coding sequence into the ACTHR locus, screening 
by Southern blotting was performed. 
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To this end, external probes, located outside of the homologous sequences, which 
detect a modification in restriction fragment length following successful recombination 
were designed (3’ probe and 5’ probe). Probes were generated by PCR on bacterial 
artificial chromosome pBACe3.6 (RP23-179K16) DNA using primers 3’Probe1 and 
3’Probe2 and 5’Probe1 and 5’Probe2, subcloned and sequenced. Figure R11 
illustrates the screening strategy for the 3’ probe-detected change in Eco RI 
restriction fragment length after recombination with the linearized 
pPNTflpCreERT2Pml vector.  
 
Southern blotting of ES cell genomic DNA followed by hybridization with the 3’ probe 
revealed three clones with the supposedly desired integration of the 
pPNTflpCreERT2Pml construct (see figure R12) but no clone with correct integration 
of pPNTflpCremyctagPml. As no clone with correct integration of the 
pPNTflpCremyctagPml vector could be retrieved during the first round of ES cell 
culture, the vector was electroporated into IDG3.2 cells a second time, treated as 
before and 384 clones were picked. 
 
 
 
4.4 Generation of ACTHR-CE2 Mice 
One of the three clones showing integration of pPNTflpCreERT2Pml was expanded 
and used for blastocyst injection in passage 18. Harvesting of the blastocysts and 
blastocyst injection was performed by the GSF mouse core facility staff, Neuherberg. 
Following blastocyst transfer into the oviducts of pseudo-pregnant foster mothers, 
nine chimeric mice were born, of which 3 exhibited germline transmission of the 
construct as evaluated by genotyping PCR of the offspring. The resulting mouse line 
was named ACTHR-CE2 and maintained by brother to sister matings (see figure 
R13).  
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4.5 Establishment of a Genotyping PCR for ACTHR-CE2 Mice 
A multiplex PCR assay using primers 5’HAss, CreAs and Exon4As was established 
for genotyping of mutant mice. In the mutant situation a 841 bp PCR product is 
generated as compared to the 385 bp product of the wild-type situation (see figure 
R14). Conditions were optimized to the following characteristics: 50 µl samples with 1 
µl primer 5’HAss (10 pmol/µl), 1,2 µl primer CreAs (10 pmol/µl) and 0,5 µl primer 
Exon4As (10 pmol/µl). Cycle number was 35. Primer annealing was carried out at 
54°C for 30 s and elongation for 1 min at 72°C. Alternatively, genotyping was 
performed by PCR using primers detecting cre or flp recombinase, neomycin 
resistance or the endogenous exon 4 of ACTHR. Of 97 male and female mice 
genotyped in the F2 generation, 18 (18,6%) were found to be wild-type and 79 
(81,4%) to carry the mutant situation. It was however, impossible to distinguish 
heterozygous from homozygous animals by PCR (please also refer to discussion 
section). 
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4.6 Characterization of the Targeted ACTHR Locus 
Notably, correct integration of CreERT2 from the linearized pPNTflpCreERT2Pml 
vector could not be verified by hybridization with the 5’ probe on Southern blots with 
ES cell DNA digested with suitable restriction enzymes due to unexpected band 
sizes and multiple bands. For probe testing, the 3’ probe and 5’ probe had initially 
been hybridized with digested pBACe3.6 (RP23-179K16) DNA (derived from strain 
C57Bl/6). With the tested restriction digests, hybridization had resulted in the 
restriction fragment lengths predicted from the online mus musculus sequence of 
www.ensembl.org (data not shown). However, when IDG3.2 genomic DNA (hybrid 
DNA from strains C57Bl/6 and 129Sv) was hybridized with the respective probes, 
unexpected band numbers and sizes were detected. Therefore extensive efforts 
were undertaken to characterize the wild-type and the recombinant locus in IDG3.2 
cells by Southern blotting with internal and external probes. Figure R 15 shows a 
representative Southern blot that illustrates the influence of the genetic strain 
background on restriction length polymorphism. The extent to which restriction length 
in the murine ACTHR locus is polymorphic depending on the mouse strain can be 
estimated from figure R16. 
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In order to verify the position of restriction sites as described by the ensembl mus 
musculus online sequence at www.ensembl.org, PCRs were run on the different 
genomic DNA templates using primer pairs HindSs/As, EcoSs/As and BamSs/As. 
These primers are located up- and downstream the supposed restriction sites. 
Lengths of PCR products were compared to predicted lengths and PCR products 
digested with the respective enzymes (see figure R17).  
 
 
 
As an alternative to detection by Southern blotting, correct integration of the 
CreERT2 targeting construct into IDG3.2 ES cells was attempted to be verified by 
long range PCR with primers pairs spanning the entire length of the homologous 
arms (see figure 18).  
 
 
 
This strategy was pursued in a combined long range/nested PCR approach. PCRs 
results however were inconclusive, with either not the predicted or multiple bands 
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(data not shown). In summary, neither Southern blotting nor PCR allowed verification 
of the desired recombination events. 
 
4.7 Characterization of ACTHR-CE2 Mice 
4.7.1 Evaluation for Flp Recombinase Mediated Selection Cassette 
Excision 
As evaluated by flp recombinase detecting PCR, ACE-promoter driven auto-excision 
of the neomycin selection cassette was unsuccessful. Breeding to universal Flp 
deleter mice, however, resulted in the abolishment of the frt-site flanked region (data 
not shown). 
4.7.2 Phenotyping of ACTHR-CE2 Mice 
On a phenotypic level, ACTHR-CE2 mice were furthermore preliminarily 
characterized with respect to body weight, adrenal weight, overall adrenal 
morphology and corticosterone release following ACTH stimulation or restraint 
stress. No significant differences were found between ACTHR-CE2 and wild-type 
mice (data not shown). 
4.7.3 Evaluation of Cre Expression by RT-PCR and Western Blotting 
Total RNA from ACTHR-CE2 mice identified as heterozygous for CreERT2 
integration was isolated, cDNA was generated and PCR using primers MAR-1 and 
Cre3 was performed to detect CreERT2 mRNA. However, CreERT2 mRNA could not 
be detected despite extensive PCR optimization efforts. Moreover, Western blotting 
with an antibody directed against the human estrogen receptor ligand binding domain 
did not show immunoreactivity on proteins of the expected size (see figure R19). As 
a consequence of the lack of identifiable cre mRNA and protein and the difficulties to 
characterize the genomic structure at the integration site, breeding of the ACTHR-
CE2 mice was discontinued. 
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4.8 Generation of Constructs pMC2RcreMYC and pMC2RcreERT2 
In the following sections, the generation of novel constructs targeting the murine 
ACTHR locus for the introduction of coding sequences of a constituitively active cre 
variant, CreMYC, and an inducible form, CreERT2, is described. These constructs 
are designed to overcome the difficulties encountered with the targeting vectors 
pPNTflpCremyctagPml and pPNTflpCreERT2Pml outlined above as a consequence 
of which breeding of ACTHR-CE2 mice was discontinued (refer also to discussion). 
In contrast to these classical knock-in constructs, the novel targeting constructs 
pMC2RcreMYC and pMC2RcreERT2 were integrated by REd/ET-cloning into a 
cosmid. This cosmid comprises approximately 43 kb of murine genomic DNA from 
the ACTHR locus. The recombinant cosmid will be used for homologous 
recombination in embryonic stem cells. As compared to the prior constructs, the 
selection strategy with neomycin during ES cell culture is maintained. However, no 
negative selection marker like thymidine kinase is used. To enable selection during 
ET cloning, an ampicillin resitance cassette is included. In order to facilitate detection 
of cre recombinase positive cells in the resulting mouse, an enhanced version of 
yellow fluorescent protein (Nagai et al., 2002) is additionally cloned into the targeting 
vectors. 
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4.8.1 Generation of Homologous Sequences and Cre 
4.8.1.1 5’ Homologous Sequence and Cre Open Reading Frame 
The 5’ homologous region required for homologous recombination into the targeting 
cosmid MPMGc121E06653Q2 along with the cre ORF were amplified by PCR from 
pPNTFlpCremyctagPml using primers 5’HAfw (adding a Hind III and a Pme I 
restriction site) and 5’HArev (adding a custom made multi cloning site comprising Aat 
II, Fse I, Sal I and Asc I restriction sites). The introduction of the Aat II restriction site 
results in a silent mutation in the last amino acid of the cre-ORF (Asp > Asp). The 
resulting PCR product of 1529 bp was subcloned into pCRII-TOPO vector 
(Invitrogen), sequenced and checked for homology to the targeting cosmid 
sequence. To abolish undesired restriction sites from the pCRII-TOPO (Invitrogen) 
multi cloning site, a Hind III digestion was performed and the vector backbone 
religated, constituting the new vector p5’HAPCR (see figure R20/1). 
 
4.8.1.2 3’ Homologous Sequence 
The 3’ homologous region required for homologous recombination via ET-cloning into 
the targeting cosmid MPMGc121E06653Q2 was generated likewise by PCR on 
pPNTFlpCremyctagPml using primers 3’HAfw (adding a multi cloning site with Asc I, 
Pac I and Xho I restriction sites) and 3’HArev (adding a Pme I and an Apa I 
restriction site). The 690 bp PCR product was subcloned into a pCRII-TOPO vector 
(Invitrogen) resulting in vector p3’HAPCR which was sequenced (see figure R20/2) 
and sequence homology to the targeting cosmid was confirmed. 
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4.8.2 Generation of Cloning Cassettes 
4.8.2.1 Improved Yellow Fluorescent Protein (Fragment 1) 
Fragment 1 comprises the coding sequence for the improved yellow fluorescence  
protein (YFP) Venus. It shows faster maturation and higher tolerance to low pH and 
chloride ions than conventional YFP. Absorption maximum of Venus is at 515 nm, 
emission maximum at 528 nm (Hadjantonakis et al., 2003;Nagai et al., 2002). 
Fragment 1 was generated by PCR with primers IVS-Aat and IVS-Sal on template 
vector 193_IRESVenus (obtained from Claudia Seisenberger, GSF Neuherberg). For 
cloning purposes, Aat II and Fse I restriction sites were added on the 5’ terminus and 
a Sal I site on the 3’ terminus of fragment 1 by the PCR primers. The 1363 bp PCR 
product was subcloned and sequenced (see figure R21/1). To express the Venus 
protein, an encephalomyelocarditis virus derived internal ribosomal entry site (IRES) 
is utilized  (Vagner et al., 2001). When coupled to an expressed gene, it allows the 
cap-independent translation of Venus from a bicistronic mRNA in mammalian cells 
via entry of the 40S ribosomal subunit at the IRES. Sequencing revealed a guanine 
to adenine mutation in base pair position 481 which was also detected on the 
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template vector. Funtionality of the IRESVenus construct was therefore verified by 
transfection into Y1 murine adrenocortical cells (data not shown). 
4.8.2.2 SV40 Polyadenylation Signal (Fragment 2) 
Fragment 2 containing a simian virus 40 polyadenylation signal (SV40 pA) was 
amplified by PCR from vector pPNTFlpCremyctagPml using primers SV40-Sal and 
SV40-Asc. Through primer SV40-Sal a Sal I restriction site was added. The resulting 
311 bp PCR product was subcloned and sequenced (see figure R21/2). 
4.8.2.3 Neomycin Resistance (Fragment 3) 
Fragment 3, comprising a neomycin resistance gene (Neo) under control of the 
constitutively active phosphoglycerate kinase-1 promoter (PGK), was amplified from 
vector pPNT4 (obtained from Jan Deussing, MPI of Psychiatry Munich) using primers 
PNeo-PacI und PNeo-AscI, adding a Pac I and an Asc I restriction site (see figure 
R21/3). The resulting 1617 bp PCR product was subcloned and sequenced. 
4.8.2.4 Ampicillin Resistance (Fragment 4) 
Fragment 4, an ampicillin resistance cassette, was amplified by PCR from vector 
pcDNA3.1(+) (Invitrogen) using primers prAMP-Pac and AMP-frt-Xho. With these 
primers, a Pac I restriction site was added at the 5’ end and a frt site and a Xho I 
restriction site at the 3’ end of fragment 4. The 1104 bp PCR product was subcloned 
and sequenced (see figure R21/4). The functionality for selection in bacteria was 
verified by eliminating the endogenous ampicillin resistance cassette in the vector 
backbone of the PCRII-TOPO (Invitrogen) subcloning vector and subsequent 
selection with ampicillin. 
4.8.2.5 Mutated Estrogen Receptor Ligand Binding Domain (ERT2) 
The ligand binding domain of CreERT2 was generated by PCR on vector pCAG-
creER(T2)-bpA SS1 (gift of Ralf Kühn) using primers CREE-Aat and CREE-FseNeu 
thereby adding a Fse I restriction site to the 3’ end of the LBD. The resulting 965 bp 
PCR product was subcloned to form vector pERT2 which was subsequently 
sequenced (see figure R21/5). 
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4.8.3 Assembly of Vectors pMC2RcreMYC and pMC2RcreERT2 
4.8.3.1 Ligation of Fragments 1 and 2 into p5’HAPCR 
Fragment 2 (SV40 polyadenylation signal) was ligated into the restriction sites Sal I 
and Asc I of p5’HAPCR. The resulting vector p5’HAF2 was sequenced for correct 
integration of fragment 2. Ligation of fragment 1 (IRESVenus) into p5’HAF2 was 
subsequently performed using restriction sites Aat II and Sal I. The resulting vector 
was named p5’HAF1F2 and sequenced for correct integration (see figure R22). 
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4.8.3.2 Ligation of CreERT2 c-Terminus and Ligand Binding Domain into 
p5’HAF1F2 
The c-terminal part of CreERT2 and the mutated estrogen receptor ligand binding 
domain were ligated into the Aat II and Fse I restriction sites of p5’HAF1F2. To this 
end, p5’HAF1F2 was digested with Bgl II/Aat II and Bgl II/Fse I respectively and the 
desired backbone fragments 4465 bp and 2622 bp of size were isolated. Triple 
ligation between these two backbone fragments and the Aat II/Fse I fragment of 
pERT2 was performed. The resulting vector was named p5’HAF1F2ERT and 
sequenced (see figure R23). The introduction of an Aat II recognition site for ease of 
cloning results in an replacement of the first amino acid of the ERT2-LBD (leucine to 
valine). As both amino acids are of the hydrophobic type, a strong functional effect of 
this replacement appears unlikely. 
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4.8.3.3 Ligation of CreMYC c-Terminus into p5’HAF1F2 
The c-terminal part of the CreMYC was generated by annealing the linker 
oligonucleotides CREM-c and CREM-ncneu. As depicted in figure R, the annealed 
linker shows compatiple cohesive overhangs for ligation into the Aat II and Fse I 
restriction sites in p5’HAF1F2. As the usual screening for correct integration by 
restriction digestion was not possible for the size and lack of restriction sites of the 
inserted linker, colony PCR was performed for clone screening using 
oligonucleotides CreConnect and CREM-ncneu as primers. Positive clones carrying 
the desired vector which was named p5’HAF1F2MYC were identified and sequenced 
(see figure R23). 
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4.8.3.4 Ligation of Fragments 3 and 4 into p3’HAPCR 
Fragment 3 (frt-PGK-Neo) was ligated into p3’HAPCR using restriction sites Asc I 
and Pac I. The resulting vector was named p3’HAF3 and sequenced for correct 
integration. For subsequent ligation of fragment 4 (ampicillin resistance cassette) into 
p3’HAF3, triple ligation between the 4638 bp Xho I digested vector backbone 
fragment, the 1658 bp Pac I and Xho I digested backbone fragment and fragment 4 
digested with Pac I and Xho I was performed. Clones showing the desired ligation 
event were identified by restriction digestion and sequencing and the resulting vector 
was named p3’HAF3F4 (see figure R24). 
 
 
 
4.8.3.5 Completion of the Targeting Constructs pMC2RcreERT2 and 
pMC2RcreMYC 
The targeting construct pMC2RcreERT was completed by triple ligation of the 3406 
bp Asc I/Apa I fragment of p3’HAF3F4 with the 2809 bp Asc I/Cla I and the 5168 bp 
Apa I/Cla I vector backbone fragments of p5’HAF1F2ERT2 (see figure R25). 
Escherichia coli clones carrying the desired vector were identified by restriction 
digestion (see figure R26) and the targeting vector pMC2RcreERT2 was sequenced 
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entirely. Mutations were detected in the CreERT2 ligand binding domain which was 
therefore replaced by ligation of a correct ERT2 ligand binding domain into the Aat II 
and Fse I sites of pMC2RcreERT2. 
 
For completion of the targeting construct pMC2RcreMYC the 3406 bp Asc I/Apa I 
fragment of p3’HAF3F4 was ligated with the 1894 bp Asc I/Cla I and the 5168 bp Apa 
I/Cla I vector backbone fragments of p5’HAF1F2MYC in a triple ligation. E. coli 
clones carrying the desired vector were identified by restriction digestion (see figure 
R26) and vector pMC2RcreMYC was sequenced for correct ligation. Complete 
sequencing of the vector was not performed as only one cloning step differs between 
pMC2RcreMYC and pMC2RcreERT2 which was entirely sequenced as described 
above. 
 
In order to electroporate the targeting constructs into E. coli containing cosmid 
MPMGc121E06653Q2, vectors pMC2RcreMYC and pMC2RcreERT2 were digested 
with Pme I and the 6607 bp and 7522 bp inserts were isolated by gel extraction. 
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In summary, the described targeting vectors both contain a cre coding sequence, 
either constituitively active or inducible by tamoxifen. An improved yellow fluorescent 
protein sequence (Venus) to be translated by ribosomal binding to an IRES site is 
coupled to the cre sequences. Antibiotic resistances that serve as selection marker 
during ET cloning or ES cell culture are flanked by frt sites and can thus be removed 
by flp recombinase mediated excision. 
 
 
 
4.9 Recombineering of pMC2RcreMYC and pMC2RcreERT2 into the 
Targeting cosmid 
In order to complete the targeting cosmids CosCremyc and CosCreERT2, 
homologous recombination between cosmid MPMGc121E06653Q2 and the Pme I-
digested inserts of vectors pMC2RcreMYC and pMC2RcreERT2 was performed by 
Red/ET-cloning (see figure R27). Bacterial clones carrying the desired, homologously 
recombined cosmids were identified by colony PCR using primers pre5’HA and 
CreOutw.  Homologous recombination was then verified by sequencing using primers 
pre5’HA, CreOutw, post3’HA and frtOutw. 
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5 Discussion 
5.1 Overview 
In the first part of the discussion, the rationale for the generation of cre mouse lines 
that allow DNA recombination specifically in the adrenal cortex is given. In the 
second part, the two strategies chosen in this thesis to generate mice with cre 
expression under the control of the ACTHR promoter are discussed. The initial 
strategy pursued, a classical knock-in strategy lead to the generation of the ACTHR-
CE2 mouse line. Possible reasons for the lack of cre expression in the adrenals of 
these mice are discussed with a special emphasis on the effects of genetic 
heterogenity between inbred mouse strains. Subsequently, the generation of 
constructs for cosmid transgenic mice in order to overcome the problems 
encountered with the first strategy is discussed. In an outlook, the necessary steps 
for generating mouse lines on the basis of these novel cosmid targeting constructs 
are described. Finally, future applications of adrenocortical cre mice are outlined. 
Exemplarily, CRHR1 is chosen, a target gene with well-known involvement in 
psychiatric pathology. How targeted gene disruption may be applied to generate a 
mouse model for adrenocortical carcinoma serves as a second example. 
5.2 Rationale 
A powerful way to infer the role of human genes is to analyze the expression and 
function of homologous genes in model organisms, such as the mouse. Traditionally, 
this was achieved by generating classical gene knock-out or overexpressing mice 
although this broad approach has obvious drawbacks. As the gene is disrupted (or 
overexpressed depending on the experimental strategy) in every cell of the organism, 
the specific function of the gene in a certain tissue may be obscured by its function in 
another tissue. Likewise, as the gene of interest is disrupted from conception 
onwards, its function during embryogenesis may preclude the interpretation of its 
function in adult animals, e.g. by an embryonic lethal phenotype in the most drastic 
case. Conditional and inducible gene targeting, i.e. activation of targeting constructs 
in a cell-type-specific and/or time dependent manner, are methods to overcome 
these disadvantages (see also introduction to this thesis). Primary aim of this project 
was to generate tools that allow conditional and inducible control of gene expression 
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in the mouse adrenal cortex in order to specifically study gene function in this organ 
compartment (see figure D1). 
 
 
 
Several systems, which are based on two fundamental principles, transcriptional 
transactivation and site-directed DNA recombination, are available to achieve 
conditional control of gene expression in the mouse (Branda and Dymecki, 
2004;Sorrell and Kolb, 2005). Although characterized by reversibility of activation, 
transcriptional transactivation systems have not found as extensive use as the DNA 
recombination based approaches. Both transcriptional transactivation methods, the 
lac (Scrable, 2002) and the tet (Corbel and Rossi, 2002) system are amongst other 
reasons impaired by the necessity to generate operator responsive promoters for the 
genes of interest which may require extensive cloning and testing procedures. Of the 
site-directed DNA recombination systems, flp recombinase is usually reserved for 
working tasks such as the removal of selection markers as in this thesis (Glaser et 
al., 2005). The ΦC31 recombinase (Thyagarajan et al., 2001) and the recent 
discovery of the cre related, heterospecific dre recombinase (Sauer and McDermott, 
2004) will further extend the tool set for site-directed mutagenesis, but as Glaser et 
al. point out, cre-mediated DNA recombination is today “the sharpest tool in the box” 
(Glaser et al., 2005). Cre recombinase mediates DNA recombination between two of 
its 34 bp target sites, the so called loxP sites, which allows a multitude of genetic 
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experiments amongst them gene activation and inactivation experiments (see also 
introduction to this thesis).  
 
Although numerous cre mouse lines exist that cover many tissues and 
developmental stages, no cre mouse line was yet established with reliable 
expression of cre in the adrenal cortex, although recombinase activity in the adrenal 
gland can be found in several cre lines originally designed for specificity to other 
tissues including the αGSU-cre (Cushman et al., 2000), the TH-cre (Lindeberg et al., 
2004), the PSA-cre (Ma et al., 2005) and the INHA-iCre (Jorgez et al., 2006). All of 
these lines however, do not express cre in the adrenal cortex but in the adrenal 
medulla or alternatively, expression in the adrenal cortex is low and heterogenous, 
while expression in other tissues is high. A novel, truly adrenocortical cre mouse line 
therefore would be complementary to the already existing lines.  
 
5.3 Driving Cre Expression by the ACTHR Promoter 
As discussed, the ultimate aim of this thesis consists in generating a mouse line with 
reliable expression of cre recombinase restricted to the adrenal cortex. In order to 
drive cre expression in a tissue-specific manner, the endogenous ACTHR promoter 
receptor was chosen. This choice offers the additional benefit, that homozygous 
ACTHR cre knock-in mice constitute classical ACTHR knock-out mice as the ACTHR 
coding sequence is replaced by a cre recombinase open reading frame. Up to now, 
no ACTHR knock-out mouse has been published which adds further interest to the 
generation of ACTHR cre knock-in mice. The evaluation of suitability of this promoter 
choice to drive cre expression requires discussion of two variables, first, strength of 
expression, second, specificity of expression. Of these two, strength of expression 
appears less of an issue, as even very low expression will eventually lead to a 
considerable recombination efficiency because cre-mediated DNA recombination is 
an irreversible and therefore accumulating event (Nagy, 2000). If cre expression can 
be limited effectively to the adrenal cortex or at least to a subset of tissues including 
the adrenal cortex is more difficult to answer. 
 
In theory, the use of an endogenous promoter to drive a deliberately introduced 
exogenous gene will restrict its expression to the domains of expression of the 
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naturally occuring product of the endogenous gene (Rickert et al., 1997). This holds 
true with some exception such as e. g. in cases that expression is additionally 
influenced by genomic position effects like in some classical transgenes (Branda and 
Dymecki, 2004). At the initiation of the project, ACTHR mRNA had been detected in 
the adrenal cortex of adult mice (Xia and Wikberg, 1996), namely in the the zona 
glomerulosa and zona fasciculata and in only a few scattered cells in the adrenal 
medulla. The latter could correspond to scattered cortical cells which are known to be 
present in the medulla (Ehrhart-Bornstein et al., 1998).  ACTHR mRNA could also be 
found in adipose tissue where ACTHR activation exerts a potent lipolytic effect 
(Boston and Cone, 1996). In contrast, there was no detectable ACTHR mRNA in 
spleen, testis, liver, lung, heart, brain and kidney (Cammas et al., 1997). ACTHR 
promoter driven cre expression consequently was expected to mimic this pattern, 
resulting in cre activity mainly in the steroid producing cells of the adrenal cortex and 
to a lesser extent in fat cells. 
 
More recent publications however, have revealed that the ACTHR can additionally be 
found in murine pancreatic islet cells of adult mice (Al-Majed et al., 2004), on certain 
leukocyte populations (Johnson et al., 2001) and most importantly, in a variety of 
tissues during prenatal development (Nimura et al., 2006). Expression was confirmed 
in adrenal gland (developmental day 13.5 (E13.5) into adulthood), testis (E13.5 to 
E18.5), genital ridge and ovary (E11.5 to E12.5 and E13.5 to E18.5 respectively), 
mesonephros (E11.5 to E12.5), metanephros (E12.5 to E18.5), lung (E11.5 to 
E14.5), brain and spinal cord (E11.5 to E13.5), choroid plexus (E13.5 into adulthood) 
and the dorsal root and trigeminal ganglia (E13.5 to E15.5). This widespread 
expression during embryogenesis has important consequences for ACTHR promoter 
controlled cre expression. As pointed out earlier, cre mediated DNA recombination is 
a cumulative event. With the use of a constituitively active cre, all cells from first cre 
expression in these cells onwards – and likewise all cells derived from them – will 
show a recombinant genotype. In the light of the extensive prenatal ACTHR 
expression in the mouse, cre-mediated DNA recombination by an ACTHR promoter 
driven constitutively active cre may thus not be limited to the adrenal cortex.  
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This potential drawback requires some attention: First of all, it depends on the 
experimental questions in how far cre expression in other tissues will confound 
results that were primarily intended to represent the adrenal cortex only. Such 
confounding influence will supposedly be high in cases like secretory molecules with 
tissue non-autonomous effects and low in genes with expression that is a priori 
restricted to the adrenal cortex. Secondly, the apparently broad promoter activity 
during embryogenesis can be entirely counteracted by using an inducible cre which 
can be activated later in life. The ACTHR promoter controlled CreERT2 in our case, 
may be expressed during embryogenesis, recombinase activity however is induced 
only after tamoxifen administration. The developmental state and the extent of 
expression can thus be chosen depending on experimental interest. Thirdly, the 
widespread expression of the ACTHR in prenatal development can be considered an 
unexpected, but highly welcome research opportunity as the developmental functions 
of the ACTHR in tissues other than the adrenal cortex is entirely unclear. 
Homozygous ACTHR cre knock-in mice, i. e. classical ACTHR knock-out mice, will 
be valuable tools to investigate them. The knock-out phenotype that was originally 
expected from the expression and function in the adult animal would likely have been 
mainly caused by glucocorticoid deficiency due to the lack of ACTH signalling. A 
possible role of the ACTHR during embryogenesis in contrast renders the knock-out 
phenotype virtually unpredictable and therefore greatly enhances its interest.  
 
Still, the question remains, if there are alternative promoters available that would 
more readily restrict gene expression to the adrenal cortex. Besides gene promoters 
of steroidogenic enzymes, especially the 21-hydroxylase promoter, (Morley et al., 
1996) and a 0.5 kb promoter fragment in combination with a 3.5 kb intronic region of 
the mouse vas deferens protein (MVDP) gene (also termed akr1-b7) (Martinez et al., 
1999) (bi-Dargham et al., 2000) have been used with some success for 
adrenocortical-specific transgene expression. Notably, like with the ACTHR 
(Cammas et al., 1997), restriction to adrenocortical cells seems to be at least partly 
conferred by SF-1 response elements in all these cases, which put possible 
advantages of one promoter over the other into question. The determination of the 
exact expression pattern is however not determined by SF-1 alone but rather by 
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specific transcription factor combinations or yet unidentified cell-specific factors (Val 
et al., 2004) which can therefore so far not be used for mouse transgenesis. 
 
In summary, controlling cre recombinase by the endogenous ACTHR promoter may 
not perfectly restrict expression to the adrenal cortex of adult mice. However, this 
promoter choice is certainly justified by the lack of better alternatives and the 
possibility to avoid cre activation during embryogenesis by means of an inducible cre. 
The supposed widespread expression furthermore opens additional research 
opportunities besides the elucidation of gene function in the adrenal cortex. The 
characteristics of the strategies that were chosen for targeting of the ACTHR locus 
will be discussed in the following section. 
 
5.4 Strategy One: Classical Knock-In Vectors 
The fundamental structure of knock-in vectors with homologous arms, selection 
markers and the gene-to-be-introduced has been discussed extensively elsewhere 
(Joyner, 2000). Discussion will therefore focus on the choice of the cre variants and 
the use of a self-excizing selection cassette which are issues specific to 
pPNTflpCremyctagPml and pPNTflpCreERT2Pml, the classical knock-in vectors 
constructed and utilized in this thesis project initially (see figure D2). 
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5.4.1 Choice of Constituitively Active Cre Variant 
As a constituitively active cre variant, a cre tagged with an epitope from the human c-
myc gene, was chosen for the generation of the targeting vector 
pPNTflpCremyctagPml. The tagging of proteins with small epitopes improves their 
immuno-detectability which facilitates expression studies. In the case of cre, tagging 
appears useful as the commercially available and published cre-antibodies (Schwenk 
et al., 1997) show only limited specificity (Ralf Kühn, personal communication). In 
contrast, the monoclonal antibody (Ab) against the human c-myc epitope is well 
characterized (Evan et al., 1985). In the first report on immunological tagging of a cre 
recombinase the authors used an epitope from the herpes simplex virus (HSV). In 
transgenic mice generated with this HSV-tagged cre, recombinase activity was fully 
retained and the cre protein was readily detectable by a monoclonal anti-HSV Ab 
(Stricklett et al., 1998). Furthermore, Watanabe et al. recently published the 
generation of a myc- and his-tagged cre variant that exerted full cre activity and 
detectability in cell culture and in an in-vivo intraoviductal injection assay (Watanabe 
et al., 2006). However, to my knowledge, no mouse line expressing a solely myc-
tagged cre recombinase has been published so far. Generation of a Cre-myc-tag line 
therefore will provide the proof-of-principle for the feasibility of this approach in mice 
along with the generation of mice with constitutive cre activity in the adrenal cortex. 
5.4.2 Choice of Inducible Cre Variant 
The ideal genetic switch was defined as enabling low or zero basal gene activity 
when switched “off” and high levels of gene activity when switched “on” (Lewandoski, 
2001). Only under these stringent conditions reliable conclusions can be derived from 
conditional gene expression experiments as high background activity and low 
inducibility both lead to diminished differences between experimental and control 
animals. When compared to other inducible cre variants available today, CreERT2 
comes closest to these requirements and is consequently used in this thesis. 
CreERT2 is a cre recombinase fused to a mutated human estrogen receptor LBD 
that comprises three point mutations (G400V/M543A/L544A) (Feil et al., 1997). 
These mutations render the ERT2-LBD insensitive to estrogen binding, but allow a 
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very high inducibility following tamoxifen administration even at comparatively low 
doses. In an attempt to further improve the characteristics of CreERT2, modified 
versions of it have been generated. The codon usage improved version iCreERT2 
was designed to achieve higher cre activities after induction. The ERiCreER variant 
on the other hand with a codon-usage improved cre fused to ERT2-LBD on both 
carboxy- and amino-terminus was intended to allow an even tighter control in the 
absence of tamoxifen while maintaining sufficient inducibility. However, none of these 
modified cre recombinases showed clear advantages over CreERT2 in cell culture 
(Casanova et al., 2002) and they have consequently not been widely used for the 
generation of transgenic mice.  
 
In contrast to its two variants, CreERT2 itself has been successfully used in a variety 
of tissues including mouse skin (Indra et al., 1999), smooth muscle (Kuhbandner et 
al., 2000), adipose tissue (Imai et al., 2001), bone (Kim et al., 2004), glia cells (Leone 
et al., 2003) (Mori et al., 2006) (Hirrlinger et al., 2006) and melanocytes (Yajima et 
al., 2006). The most recently published CreERT2 mouse line with expression in 
neurons of the dorsal root ganglia is characterized by complete absence of cre 
activity without tamoxifen. Activity after tamoxifen administration was found to be only 
about 10% of the activity of a constituitively active cre expressed under the identical 
promoter. After experimental exclusion of cytosolic CreERT2 sequestration by high 
levels of Hsp90, the authors favor low tissue penetrance of tamoxifen as possible 
explanation (Zhao et al., 2006). They argue, that increased doses of tamoxifen would 
ultimately lead to a higher induction efficiency. Unfortunately, mice display symptoms 
of toxicity for orally administered tamoxifen amounts of more than 2 mg/day. 
 
As in all other cases, the minimum dosage and time of application of tamoxifen for an 
optimal induction of cre activity will also need to be established in ACTHR promoter 
controlled cre mice. It appears plausible to assume that the adrenal gland as a highly 
perfused endocrine organ will show sufficient penetration of tamoxifen. The amounts 
required for induction will therefore likely be considerably lower than for example in 
the neuronal or glial CreERT2 variants and will thus not reach the toxic range. In the 
case of ACTHR promoter controlled cre mice, the differential tissue penetrance may 
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even be of benefit in the light of a possible expression of cre in adipose and other 
tissue: Tissue specificity might be titrable.  
 
As a further point of note, the transcription of ACTHR mRNA is upregulated following 
ACTH stimulation in cultured human and mouse cells (Mountjoy et al., 1994). 
Consequently, cre recombinase expression might be increased by ACTH 
administration in cre lines as well in which expression is controlled by the 
endogenous ACTHR promoter. ACTH administration could possibly modify the 
recombination kinetics by accelerating recombination or increasing the maximum 
recombination efficiency. Conversely, adrenostatic compounds such as 
aminoglutethimide and metyrapone suppress ACTHR expression (Fassnacht et al., 
1998) and might be used to slow down recombination. 
 
With respect to detectability as discussed earlier for the myc-tagged cre variant, 
CreERT2 offers the advantage of immuno-reactivity with antibodies directed against 
the human estrogen receptor (ER) ligand binding domain. These are more specific 
than the available cre-antibodies (Ralf Kühn, personal communication) and were 
successfully used in this thesis for detection of the CreERT2 protein by Western 
blotting. 
 
5.4.3 Selection Cassettes 
Two antibiotic resistance cassettes are included in the classical knock-in constructs 
for selection of clones during embryonic stem cell culture: Firstly, a phosphoglycerate 
kinase I promoter driven thymidine kinase for negative selection (also refer to results 
chapter) which follows well established priniciples and will not be discussed further, 
secondly, the phosphoglycerate kinase I promoter driven neomycin resistance 
cassette for positive selection. In contrast to cassettes for negative selection, positive 
selection cassettes are located in between the homologous arms,  so that they are 
not lost during homologous recombination. However, as the neomycin gene was 
shown to influence expression of adjacent genes, it needs to be removed after the 
selection process (Pham et al., 1996). To this end, the marker is usually flanked with 
frt sites that allow flp-mediated DNA recombination and thereby cassette excision 
(compare also design of the recombineering vectors depicted on figure D3). This 
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approach requires time-consuming manipulations, either flp expression in ES cells or 
breeding to flp expressing mice. The latter approach furthermore will likely lead to 
mosaic cassette removal only as flp activity is not uniform in all cells (Rodriguez et 
al., 2000).  
 
To circumvent these common problems, v. Waldenfels and Deussing in our group 
generated a novel positive selection cassette which was tested in vectors 
pPNTflpCremyctagPml and pPNTflpCreERT2Pml in a proof-of-principle experiment. 
This cassette is flanked with frt sites and carries a neomycin resistance gene 
expressed under a phosphoglycerate kinase I promoter (PGK) and a flp recombinase 
gene which is driven by an ACE promoter. The ACE promoter is active during 
spermatogenesis and was therefore thought to a activate flp expression during sperm 
cell formation effectively leading to self-excision of the cassette. A similar approach 
was taken by Bunting et al. who generated mice with an ACE promoter driven, cre-
mediated self-excision cassette (Bunting et al., 1999). In contrast to these mice, the 
ACTHR-CE2 mice generated from construct pPNTflpCreERT2Pml failed to self-
excise, while deletion by breeding to flp expressing mice did result in cassette 
deletion. In conjunction with the failure of self excision in another mouse line 
generated in our laboratory (unpublished data), the self-excising property of the 
selection cassette unfortunately has to be considered non-functional. As flp 
recombinase  activity in mammalian cells is much lower than cre recombinase activity 
(Andreas et al., 2002) it is apparently not sufficient to cause recombination when flp 
expression is driven by the ACE promoter as in the vectors presented here. The self-
excision strategy was therefore not further pursued in subsequent constructs such as 
the cosmid targeting vectors discussed later. 
 
5.4.4 ACTHR-CE2 Mice 
As described in the results chapter of this thesis, the targeting vector 
pPNTflpCreERT2Pml was used to generate the mouse line ACTHR-CE2 by 
homologous recombination in ES cells. As desired, characterization of heterozygous 
ACTHR-CE2 revealed no significant differences to wild-type mice with respect to 
body weight, adrenal weight, gross adrenal morphology and corticosterone release 
following ACTH administration or restraint stress. Unfortunately, the mouse line also 
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showed no detectable cre expression as evaluated by RT-PCR and Western blotting. 
The functional activity of cre was consequently not tested anymore by breeding to cre 
reporter mice such as R26R (Soriano, 1999), also in the light of the required 
tamoxifen induction. Possible reasons for the lack of expression will be discussed in 
this section. 
 
Absence of expression may be caused by one or more of several factors. Firstly, the 
targeting construct itself may be non-functional. This, however, appears little 
plausible in our case as the fundamental construct design follows well established 
principles. Technical issues that could result in lack of expression such as frame shift 
mutations and absence of polyadenylation signals were excluded by analysis of the 
vector sequencing results. Secondly, the activity of the endogenous promoter at the 
target locus may be insufficient to drive expression of the exogenous gene. The 
knock-in strategy as pursued here replaces the open reading frame of the ACTHR. 
All putative regulatory elements situated up- or downstream as well as the regions 
forming the 5’ and 3’ UTRs are unaffected. Consequently, as ACTHR expression 
itself is detectable by RT-PCR and Western blotting, the exogenous gene should 
behave equally. Thirdly, the integration of the targeting construct via homologous 
recombination exactly into the desired locus failed, which is the explanation with most 
evidence in our case. 
 
Success of gene targeting in ES cells is commonly verified by one of two methods, 
Southern blotting and long range PCR of ES cell DNA. By means of Southern 
blotting, three ES cell clones were identified in this thesis that supposedly had 
undergone homologous recombination with the targeting vector pPNTflpCreERT2Pml 
(also see results chapter). One of these clones was used to generate the ACTHR-
CE2 mouse line. In an isogenic background as normally the case, a wild-type 
situation is represented on a Southern blot by a single band of a certain length 
expected from prior in silico sequence analysis. This band is constituted by the 
hybridization of the probe to both wild-type alleles that are located on the two 
homologous chromosomes. However, in our case the wild-type situation was 
characterized by two bands of different sizes in almost all digests with different 
restriction enzymes. One of the bands usually matched the expected wild-type size, 
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while the other did not. The unexpected band was therefore initially thought to be 
caused by unspecific cross-hybridization of the probe to another genomic region. 
Restriction length polymorphism by mutation of one of the alleles as alternative 
explanation was considered improbable, because a second band consistently 
appeared in different digests. At the time of ES cell clone screening, the detection of 
a third fragment showing the size expected for the recombinant band was thus taken 
as indicative for successful gene targeting by homologous recombination. 
Retrospectively however, the amount of restriction length polymorphism, i.e. 
sequence polymorphism, between the two wild-type alleles was underestimated. It 
was caused by the utilized ES cell line as will be discussed in the following section. 
 
Traditionally, almost all ES cell lines used for gene targeting are generated from 
epiblast cells of mouse strain 129 (Brook and Gardner, 1997). For unknown reasons, 
this strain has proven particularly permissive for the derivation of ES cell lines and 
the colonization of blastocysts usually gives rise to chimeric animals with high 
likelihood of germline transmission of an introduced mutation. Acceptor blastocysts in 
contrast are usually derived from strain C57Bl/6 which allows for coat color selection 
and provides better breeding efficiencies. To control for strain influence on the 
phenotype, the mutant offspring are backcrossed continously to C57Bl/6 mice in 
order to re-instate an inbred background. This procedure usually delays reliable 
phenotype analysis of mutant mice for more than one year and still does not abolish 
the influences of loci that are inherited linked to the targeted locus (Crusio, 2004). 
Backcrossing can be shortened by one generation of breedings by means of hybrid 
ES cells derived from two different strain backgrounds, so called F1 (first filial 
generation) ES cells. Their genome is constituted by homologous chromosomes that 
originate from either of the parental strains, which are substrains of 129 and C57Bl/6, 
i. e. half of their genome is already congenic to the C57Bl/6 acceptor blastocyst DNA. 
A further advantage of F1 ES cells besides speeding the backcrossing procedure 
seems to be their “hybrid vigor” which allows extended culture periods and 
manipulations while their capacity to give rise to fertile offspring is maintained (Eggan 
et al., 2001).  
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In order to generate ACTHR-CE2 mice, IDG3.2 cells (gift of Ralf Kühn) were used 
which are F1 ES cells created from breedings between strains 129S6/SvEv/Tac and 
C57Bl/6 (Schwenk et al., 2003). The possible advantages of robustness and 
shortening of breeding were however in our case outweighed by the fact that the use 
of the hybrid ES cells led to the misinterpretation of the Southern blotting results. The 
detected two bands were considered one wild-type and one unspecific band as the 
amount of genetic heterogenity between the two strains was underestimated. 
However, as later demonstrated by comparative Southern blotting, the wild-type 
situation in IDG3.2 genomic DNA is indeed characterized by extensive restriction 
length polymorphisms between the two ACTHR loci derived from either parental 
strain.  
 
The extent to which sequence disparities prevail between different mouse strains is 
only beginning to be fully recognized since the publication of the mouse genome data 
in 2002. Commercial mouse sequencing by Celera Genomics was carried out on four 
mouse strains (129X1/SvJ, 129S1/SvImJ, A/J and DBA/2J) with a total 5.3-fold 
genome coverage. The publicly funded Mouse Genome Sequencing Consortium in 
contrast was sequencing a single strain, C57Bl6/J, covering the genome 6.5-fold and 
three additional strains (129S1/SvImJ, BALB/cByJ and C3H/Hej) for only minimal 
coverage (Wade and Daly, 2005). As of August 2006, TranscriptSNPView has been 
added to the genome browser (www.ensembl.org) that allows convenient comparison 
of interstrain sequence differences identified by these sequencing projects. 
Alltogether, this genome-wide catalog displays coding single nucleotide 
polymorphism (SNP) variations from 48 mouse strains (Cunningham et al., 2006). 
Mouse haplotype information on inbred strains can also be found on 
www.broad.mit.edu/personal/claire/MouseHapMap/Inbred.htm, however up to now 
only in form of SNP lists. Another third comprehensive online source for comparative 
mouse genomics is www.informatics.jax.org, which besides extensive phenotypic 
data on multiple mouse strains since recently also offers information on inter-strain 
sequence differences.  
 
Interestingly, genetic variation between mouse strains is not homogenously 
distributed throughout the genome, which reflects the evolutionary and breeding 
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history of the inbreed laboratory mouse strains (Wade and Daly, 2005). When the 
C57Bl/6J Mouse Genome Sequencing Consortium sequence was compared to 
sample sequences from ancestral mouse strains and common inbred strains, 
genome segments were identified showing SNP frequecies of up to one SNP per 250 
bp, while other regions only comprised about one SNP per 20 kb (Wade et al., 2002). 
Between mouse strains 129S5 and C57Bl/6J, which only diverged by breeding within 
the last century (Beck et al., 2000), SNPs lead to an estimated > 100 premature 
transcriptional termination codons and > 62.000 coding changes and splice-site 
alterations (Adams et al., 2005). Yalcin et al. showed exemplarily by inter-strain 
comparison of a 4.8 Mb region on chromosome 1 which contains a quantitative trait 
locus (QTL) influencing anxiety that the unexpected haplotype complexity they 
encountered could be represented by “strain distribution patterns” (Yalcin et al., 
2004). These common patterns of alleles suggest that there is both extensive linkage 
disequilibrium and limited diversity potentially facilitating phenotypic mapping 
experiments. Besides SNPs, other types of inter-strain genetic variations include 
sequence insertions, deletions and copy number polymorphisms likewise offer 
interesting insights (Wade and Daly, 2005) but will not be discussed further. 
 
Despite extensive efforts to characterize the wild-type and the targeted locus it still 
remains enigmatic what exact genetic rearrangements occurred in the ES cell clone 
used to generate ACTHR-CE2 mice. Integration did take place as PCR testing with 
internal primers showed. Correct integration of the construct via homologous 
recombination into the exact position at the ACTHR locus however did likely not 
occur. In this case, one of the wild-type bands would have been shifted to the length 
of the recombinant band when screened with e. g. the external 3’ probe in Southern 
blotting. The appearance of an additional band points to the duplication of the binding 
site for the probe. Karyotyping of the ES cell clone used for generation of the 
ACTHR-CE2 mice however showed no obvious abnormalities (data not shown) so 
that the size of duplication must be low. Although a more detailed characterization of 
the events at the targeted locus could have been undertaken, this line of investigation 
was not pursued further for the lack of practical consequences. After all, the insert 
was unable to produce CreERT2 protein. 
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Comparability of this case to the existing literature is limited, since reports on 
aberrant gene targeting are scarce due to publication bias: Negative results are not 
published. One extremely rare exception from this rule is the publication of an 
aberrantly targeted p53 allele (Tyner et al., 2002). For unknown reasons, targeting in 
this case resulted in the unexpected deletion of p53 exons 1-6 and an approximately 
20 kb region upstream of the gene. Mice derived from these ES cells exhibited 
enhanced tumor resistance and an increased lifespan. Interestingly, like with the 
ACTHR-CE2 mice, the authors were unable to detect a truncated (p53) protein. Even 
this publication does not offer mechanistic explanations for the aberrant gene 
targeting event but benefits from the otherwise interesting phenotype of the mice. In 
conclusion, as no specific data on aberrant gene targeting is available, general 
parameters that influence gene targeting success were considered in order to modify 
the targeting strategy and to improve the targeting efficiency. Besides the length and 
design of the targeting vector and the target genetic locus (Zhou et al., 2001), two 
major factors determine the efficiency of homologous recombination: The length 
(Hasty et al., 1991) and the grade of sequence identity (te Riele H. et al., 1992) of the 
homologous regions. In the second strategy employed in this thesis for the 
generation of targeting vectors, both factors are accounted for, as will be discussed 
in the following chapter. 
 
5.5 Strategy Two: Recombineering Vectors 
In comparison with the classical knock-in vectors pPNTflpCremyctagPml and 
pPNTflpCreERT2Pml described earlier, the same cre variants were used to generate 
the targeting cosmids CosCremyc and CosCreERT2 (see figure D3). In their design, 
two points require further attention, the major being the change to a recombineering 
strategy, the minor the introduction of the Venus fluorescence marker which is 
translated by means of an internal ribosomal entry site (IRES). The choice of 
resistance cassettes for selection during recombineering and ES cell culture is 
largely determined by the cassettes present in the carrier cosmid and is therefore not 
discussed. Notably, no negative selection marker was included into the targeting 
cosmids CosCremyc and CosCreERT2. Its inclusion would have required difficult 
cloning steps and is largely unnecessary as the expected overall rate of correct 
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targeting with a cosmid is high and the usual enrichment achieved by negative 
selection low (Joyner, 2000). 
 
 
 
5.5.1 Cosmid Recombineering 
“Recombineering” refers to the cloning of DNA in E. coli by homologous 
recombination (Copeland et al., 2001). It is usually applied to large DNA vectors such 
as bacterial artifical chromosomes (BACs) and cosmids that are otherwise not easily 
modifiable. In this thesis, recombineering was used to integrate a 6.6 kb fragment of 
plasmid vector pMC2RcreMYC and a 7.5 kb fragment of plasmid vector 
pMC2RcreERT2, respectively, into the cosmid MPMGc121E06653Q2. This cosmid 
carries approximately 40 kb of strain 129/ola genomic DNA from the ACTHR locus 
which provides more than sufficient homologous DNA for subsequent gene targeting 
in ES cells. To account for sequence disparities in the homologous regions of the 
plasmid (derived from strain C57Bl/6) and cosmid (129/ola) that would decrease 
recombineering efficiency (Liu et al., 2003), longer homologies (approximately 500 
and 700 bp) than the 60 bp of the original publication were used (Zhang et al., 
1998a). 
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For the production of gene targeting vectors, recombineering has been applied most 
commonly to integrate targeting constructs into BACs (Yang and Seed, 2003) 
(Valenzuela et al., 2003). BACs carrying genomic DNA from a region of interest are 
readily available and even annotated in the genome browsers as C57Bl/6 BACs were 
used for mouse genome sequencing (Branda and Dymecki, 2004). For their size of 
around 300 kb, BACs can be identified that contain all necessary regulatory elements 
to confer normal gene expression to a transgene (Heintz, 2001). Moreover, even 
BAC transgenes are typically not subject to the strong position effects resulting in 
transgene silencing or misexpression that affect conventional constructs (Giraldo and 
Montoliu, 2001). Besides BACs, other large DNA vectors like cosmids may be used 
for gene targeting. Although to my knowledge no mouse line has been reported so 
far generated on the basis of cosmid recombineering and homologous recombination 
making our strategy the proof-of-principle for this approach, the general feasibility of 
cosmid targeting has been demonstrated in fungi (Chaveroche et al., 2000). When 
used for this purpose in mice, cosmids offer, although not characterized by the 
advantages of BACs to full extent due to their lower size of about 40 kb, the benefit of 
easier handling, especially with respect to screening of ES cell clones by Southern 
blotting or long range PCR. These assays are based on finding ES cell clones in 
which sequences within the native locus (but outside of the flanking regions shared 
by the targeting vector) have been linked to sequences unique to the targeting 
vector. Such linking of sequences can only occur in correctly targeted ES cells. In 
order to be able to use these techniques, the length of homology arms used in 
targeting vector is effectively limited to about 10 kb. This condition is granted on the 
3’ homologous region of the targeting cosmids presented here. BAC targeting on the 
other hand requires fluorescence in situ hybridization (FISH) (Yang and Seed, 2003) 
or indirect screening techniques such as the real-time PCR based “loss-of-native-
allele” approach (Valenzuela et al., 2003). 
 
The novel cosmid targeting vectors generated by recombineering are suitable to 
overcome the problem of inefficient and aberrant gene targeting encountered with the 
classical knock-in constructs pPNTflpCremyctagPml and pPNTflpCreERT2Pml 
described earlier. The homologous arms of these constructs had a combined length 
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of approximately 8 kb while the cosmid vectors comprise homologies of about 40 kb. 
Deng and Capecchi could show in extensive experiments that efficiency of targeting 
at the Hprt locus increased exponentially with the length of homologous sequence up 
to at least 14 kb (Deng and Capecchi, 1992). In how far longer homologies further 
improve recombination efficiency has not been systematically tested. It is however 
known, that longer homologies diminish the influence of disparities in their genetic 
sequence, which is the second major factor influencing targeting efficiency 
(Valenzuela et al., 2003). Te Riele et al. first showed that targeting the 
retinoblastoma gene locus with isogenic DNA was 10- to 20-fold more efficient than 
with non-isogenic DNA (te Riele H. et al., 1992). With the µ-opioid receptor locus, 
targeting between isogenic DNA was 15-fold more efficient than between non-
isogenic DNA, although the sequences between the two strains used in this 
experiments (129/Sv and C57BL/6) varied only about 2% at this locus (Zhou et al., 
2001). In fact, isogeny is such an important factor that sequence differences even in 
between substrains of 129 reduce targeting efficiency and even let some loci appear 
untargetable. For example, attempts to target a region tightly linked to Tyr on 
chromosome 7 were unsuccessful when a 129/SvJ-derived construct was 
electroporated into a 129/Sv ES cell line; however, the same construct underwent 
homologous recombination very efficiently in a 129/SvJ derived ES cell line (Joyner, 
2000).  
 
Notably, the genetic differences between different mouse strains do not only affect 
gene targeting efficiencies but also the phenotypes of the resulting offspring. For 
example, when targeting the epidermal growth factor receptor (Egfr) locus on a CF-1 
or 129/Sv background animals died prenatally, while on a CD-1 they lived for up to 3 
weeks post partum  (Threadgill et al., 1995). Even between certain substrains of 129 
there are differences in behavioral paradigms (Montkowski et al., 1997) and 
reciprocal skin grafts are rejected (Simpson et al., 1997). Unfortunately, it is 
frequently impossible to tell which exact mouse strain was used in an experiment or 
to generate a genomic library as denominations are outdated or incomplete. Strain 
names such as 129/SvJ as opposed to 129/SvJae do not facilitate precision in this 
respect (Festing et al., 1999). 
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In conclusion, the DNA for construction of targeting vectors should be ideally isogenic 
with the utilized ES cells. Alternatively, length of homology may compensate for 
sequence disparities. The cosmid targeting vectors presented here, will therefore 
likely show considerably higher targeting efficiency than the classical targeting 
vectors used before. 
 
5.5.2 Fluorescent Marker 
In order to facilitate identification of cre expressing cells, the cosmid vectors 
CosCremyc and CosCreERT2 were designed for expression of a bicistronic mRNA 
which contains the coding information for both cre recombinase and a fluorescent 
marker (Venus). Translation of the Venus fluorescent protein is granted by means of 
an IRES (see figure D3). IRESs, originally identified in picorna viruses (Pelletier and 
Sonenberg, 1988), have been found in a variety of viruses. They allow the cap-
independent translation of a bicistronic mRNA in eukaryotes by internal binding of the 
ribosomal 40S subunit to the mRNA (Vagner et al., 2001). The encephalomyocarditis 
IRES site was first used in mice by Kim et al., 1992 (Kim et al., 1992). In contrast to a 
fusion protein, the use of the IRES offers the advantage of leaving the biological 
properties of the cre recombinase unaffected as two independent proteins are 
generated from one mRNA. A possible disadvantage is the unpredictable strength of 
IRES-mediated translation. For example, in CamKIIα iCre-IRES-eGFP BAC 
transgenic mice fluorescence was found to be weak and was not detected uniformely 
in all hippocampal neurons (Casanova et al., 2001). The IRES-translated fluorescent 
marker Venus used in this thesis is a variant of the yellow fluorescent protein (YFP) 
with faster maturation and increased fluorescence yield (Nagai et al., 2002). Its 
properties may therefore compensate possible low IRES-driven expression. A Venus 
fusion protein construct has been used to visualize endoplasmatic reticulum stress 
(Iwawaki et al., 2004), but to my knowledge no IRES-Venus construct has been 
applied to the mouse so far. In summary, the inclusion of the IRES-dependent Venus 
fluorescent marker into the cosmid targeting vectors allows an indirect but rapid and 
– if needed – even in vivo detection (Hadjantonakis et al., 2003) of cells that express 
cre. 
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5.6 Outlook 
5.6.1 Towards The Generation of ACTHR Cre Cosmid Mice 
Ultimately, four mouse lines can be generated with the cosmid targeting vectors 
CosCremyc and CosCreERT2 presented in this thesis. Of these four lines, two lines 
express the constituitively active Cremyctag, one of them as transgenic, one of them 
as knock-in mouse. The two remaining lines are one transgenic and one knock-in line 
for the ACTHR promoter driven inducible CreERT2. Every one of these lines is 
characterized by inherent strengths and limitations. The widespread expression of 
the ACTHR during embryogenesis may result in too little restriction of cre activity in 
the case of the constituitively active cre. The inducible CreERT2 mouse lines on the 
other hand require tamoxifen administration for cre activation which precludes a rapid 
evaluation. The transgenic lines might be prone to position effects necessitating the 
characterization of several lines. Indeed, Lee et al. generated Eno2-Cre mice from 
both full-size BACs and from 25 kb BAC fragments. Expression domains varied 
between the two lines created from the fragment and were also different from the 
expression pattern of the full-size BAC derived line (Lee et al., 2001). The cosmid 
knock-in lines for their part might be hampered by the loss of homozygosity at the 
ACTHR locus which might influence hormonal parameters. Homozygous knock-in 
animals in contrast are of special interest as they will reveal the ACTHR knock-out 
phenotype. Thus the different lines will be complementary in the sense that 
drawbacks of one line are overcome by the other lines. In addition, the four lines 
allow addressing different sets of questions, with a functioning transgenic CreERT2 
line being most useful for the analysis of gene function in the adrenal cortex. 
 
Technically, the cosmid vectors CosCremyc and CosCreERT2 can be used in ES 
cells at the same time to generate transgenic mice, i.e. with random construct 
integration, and knock-in mice, i.e. with integration by homologous recombination. To 
facilitate clone screening by Southern blotting, no F1 hybrid but isogenic 129 derived 
ES cells will be used in order to avoid the interstrain restriction length polymorphisms 
encountered with the first targeting strategy. After identification of clones with either 
random or targeted construct integration, by Southern screening with internal and 3’ 
probes on e. g. Xho I digests, blastocyst injection will be performed as for the 
generation of ACTHR-CE2 mice. In the resulting offspring, the presence of cre and 
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Venus mRNA will be verified by RT-PCR or in situ hybridization and the presence of 
the respective proteins by Western blotting or immunohistochemistry and 
fluorescence microscopy. Subsequently, the neomycin/ampicillin selection cassette 
will be removed by breeding to mice with ubiquitous flp recombinase expression 
(Dymecki, 1996). The mouse stock will then be maintained by continuous breeding to 
C57Bl/6 mice. 
 
The characterization of cre activity will cover two main parameters, efficiency and 
spatial distribution of recombination. For the inducible CreERT2 recombinase 
leakyness, i.e. activity without tamoxifen induction, and efficiency after tamoxifen 
administration as compared to the constituitively active cre will be evaluated 
additionally. To this end, cre mice will be crossed to R26R LacZ reporter mice 
(Soriano, 1999). In these mice, a lacZ reporter gene is activated after cre mediated 
excision of a transcription termination signal. As expression from the R26 locus is 
ubiquitous, all cells with cre recombinase activity are stained by lacZ thus revealing 
the cre expression pattern. Alternatively, other cre reporter strains can be used, e.g. 
with activation of a fluorescent marker by cre recombination (Branda and Dymecki, 
2004). LacZ is however more sensitive than fluorescence detection as staining 
intensity accumulates. 
 
The characterization of ACHTR cre mice will furthermore include the demonstration 
that key biological parameters do not differ between cre and wild-type mice as this 
might obscure phenotypes in subsequent conditional gene targeting experiments with 
these mice. Phenotyping of cre mice will therefore cover adrenal hormone release 
under basal and stress conditions and adrenal morphology. Moreover, parameters 
reflecting other functions of tissues with expression of ACTH will be measured e.g. 
body weight and total fat mass as markers for adipose tissue. In the case of 
homozygous cre knock-in mice, i.e. ACTHR knock-out mice, phenotyping might lead 
to insights into yet unknown functions of the ACTHR. Which conditional gene 
targeting experiments exploiting the specific cre activity might ultimately be 
performed with the ACTHR cre mice is illustrated in the next section. 
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5.6.2 Targets for ACTHR Cre Mice 
As the cre/lox system is binary, cre mice alone are of only limited use unless they 
may serve a second function e. g. as classical knock-out mice like in this thesis. Cre 
mice however become an exceptional tool when combined with the other component 
of the system, mice with floxed target alleles. The system then does not only allow 
targeted gene disruption but also other experiments such as targeted gene 
overexpression and knock-down. In this last part of the discussion, possible fields of 
interest for gene function experiments in the adrenal cortex are presented (see figure 
D4).  
 
 
 
 
In the field of adrenocortical organogenesis, questions include the developmental 
origins of the adrenal cortex and the molecular regulation of its formation (Hammer et 
al., 2005). Targeted mutagenesis may help to better understand these processes and 
to develop models for congenital syndromes of aplasia or agenesis (Else and 
Hammer, 2005). Even in adulthood, the adrenal cortex displays constant renewal of 
steroidogenic cells and is able to compensate contralateral loss of an adrenal cortex 
by ipsilateral hyperplasia. Its underlying mechanisms and the provenience of cells 
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remain largely unknown, although a subcapsular stem cell zone is hypothesized to 
be involved (Else and Hammer, 2005). 
 
Within the human adrenal cortex, steroid hormone synthesis depends on the 
coordinated action of several enzymes. It is the differential expression of these 
enzymes within the adrenocortical zones that allows the synthesis of the wide array 
of steroid hormones secreted by the gland. However, the factors causing the 
coordinated differential expression are only incompletely understood (Hsu et al., 
2006). Targeted gene disruption of steroidogenic enzymes may improve this 
understanding and provide models for adrenocortical dysfunction. It may also be 
applied to circumvent the necessity for surgical adrenalectomy in mice as sometimes 
needed to experimentally control for endogenous glucocorticoid release.  
 
Hormone secretion from the adrenal cortex is subdued to much more regulatory 
influences than assumed in the past. Humoral and neuronal factors but also direct 
intercellular interactions play important roles besides the classical secretagogues 
angiotensin and ACTH (Ehrhart-Bornstein et al., 1998). In how far structures like gap 
junctions or molecules like serotonin modulate adrenocortical function may be 
addressed by gene targeting. One of the newly identified regulators of hormonal 
secretion from the adrenal cortex is CRHR1, whose targeted disruption will be 
discussed exemplarily in the following section. 
 
5.6.2.1 CRHR1 as Regulator of Glucocorticoid Secretion 
CRH was first purified and characterized in 1981 (Spiess et al., 1981;Vale et al., 
1981). Since then, data from patients and model organism have revealed the 
important role of CRH and its two receptors, CRHR1 and CRHR2, in mood and 
anxiety disorders (Deussing and Wurst, 2005) (see also introduction to this thesis). 
For the elucidation of these disorders, the obvious focus of research has been CRH 
function in the central nervous system (CNS). Our research group made important 
contributions to this field e. g. by generating both classical (Timpl et al., 1998) and 
conditional (Muller et al., 2003) CRHR1 knock-out mice. 
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Nonetheless, peripheral organs, especially the adrenal gland, may be crucial for a 
better understanding of affective disorders. Several lines of evidence point into this 
direction: The importance of adrenocortical steroid hormones in the brain to modulate 
behavior is well known (de Kloet et al., 2005;Holsboer, 2000). Circulating interleukin-
18 is released from the adrenal after stress, indicating a possible 
neuropsychoimmunological function of the adrenal (Sekiyama et al., 2006;Sugama et 
al., 2006). Even on the level of gross morphology, an antidepressant treatment 
reversible, increased adrenal volume determined by computed tomography has been 
reported in depressed patients (Nemeroff et al., 1992;Rubin et al., 1995). Indeed, to 
investigate adrenal function in affective disorders seems to be of utmost interest as 
evidence about the connection between major depressive disorder and somatic 
illnesses such as coronary heart disease is accumulating (Joynt et al., 2003). As 
adrenocortical glucocorticoids exert their effects on multiple central as well as 
peripheral tissues and cell types, they could represent the missing link between the 
different pathologies (Brown et al., 2004). 
 
Intriguingly, CRH, classicaly known only as ACTH secretagogue and regulator of 
brain function as pointed out already, seems to be directly implicated in the regulation 
of adrenocortical steroid hormone secretion. Strong evidence for this hypothesis is 
provided by the failure of CRHR1 knock-out mice to release corticosterone after 
ACTH stimulation (Muller et al., 2001). CRH levels in the general bloodstream are 
low, so that the existence of an intra-adrenal regulatory CRH system has been 
postulated (further evidence reviewed in Ehrhart-Bornstein et al., 1998). The 
involvement of the CRH receptor family in the production and release of 
catecholamines from the adrenal medulla has furthermore been demonstrated in a 
recent paper. To date, the physiological significance of these findings is entirely 
unclear (Dermitzaki et al., 2007). It is however tempting to speculate, that CRH might 
be involved in the differentiation of adrenal response to either somatic of 
psychological stressors. Ultimately, targeted disruption of CRHR1 in the adrenal 
cortex will help answering these questions and may also shed light on the 
morphological abnormalities encountered in the adrenals of classical CRH receptor 
knock-out mice (Preil et al., 2001). How targeted gene disruption may furthermore be 
used to generate a model for adrenocortical carcinoma, will be discussed next. 
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5.6.2.2 A Mouse Model for Adrenocortical Carcinoma 
Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Its 
incidence is approximately 1-2 per year per million population. R0 resection is the 
treatment of choice for stage I-III ACC. However most patients enventually develop 
either local recurrence or distant metastases so that overall 5-year survival ranged 
only between 23% and 60% depending on the study population. First line treatment 
for metastatic disease (stage IV) is mitotane, whose clinical efficacy remains disputed 
(Allolio et al., 2004). Unfortunately, progress in elucidating the molecular pathology 
and improving the pharmacological treatment of ACC is slowed by the absence of a 
suitable, orthotopic mouse model. The traditional in vivo models rely on the 
subcutaneous injection of Y1 cells and, more recently, of modified mouse myeloma 
cells (Ortmann et al., 2004). In an attempt to generate novel stable tumor cell lines, 
targeted SV40 T antigen transgene expression in the mouse adrenal cortex lead to 
tumor formation (Mellon et al., 1994) (Sahut-Barnola et al., 2000). Homozygous 
Inhibin α (Inha) knock-out mice develop adrenal tumors, in case prior death due to 
gonadal tumors is prevented by gonadectomy. However, this rodent model appears 
of only limited value as the contribution of Inha in human tumorigenesis is unclear 
(Stratakis, 2003). 
 
Mice with targeted, adrenocortical disruption of gatekeeper genes such as p53 or 
PTEN may be able to provide a more reliable ACC model. These molecules are 
known to be involved in the formation of a least a subset of adrenocortical tumors 
(Stratakis, 2003) and the generation of tumor models by cre-mediated conditional 
mutagenesis of p53 (Attardi and Donehower, 2005) and PTEN (Kishimoto et al., 
2003) has already been successful in a variety of organs and tissues. Mice with 
floxed p53 and PTEN alleles are therefore already available. The development of 
tumors in other tissues that confer early-onset lethality as in the classical knock-outs 
of these genes can be elegantly avoided by the tissue specificity of cre expression. 
One example for this approach is the PSA-cre mediated disruption of PTEN in the 
prostatic gland. With this model, the embryonic lethal phenotype of homozygous 
conventional PTEN knock-out mice was bypassed and the role of PTEN in the 
development of prostate neoplasias could be demonstrated (Ma et al., 2005). The 
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use of the inducible adrenocortical CreERT2 mouse line would furthermore enable 
the determination of the onset of tumor formation by tamoxifen administration. The 
possibility to generate conditional double mutants, e. g. with targeted disruption of 
p53 and the telomerase RNA component mTERC (Attardi and Donehower, 2005) 
gene, might even enhance the value of adrenocortical cre mice for providing ACC 
models. 
 
5.7 Conclusion 
In conclusion, the number of targets for cre-mediated genetic manipulation in the 
adrenal cortex is extensive and will further increase with the number of available 
floxed genes. Large scale mouse mutagenesis consortia such as the European 
conditional mouse mutagenesis project EUCOMM (Schnutgen et al., 2005) (Glaser et 
al., 2005) have recently been established with the aim to generate conditional alleles 
for every known gene (Grimm, 2006). The number of target strains will therefore 
steadily increase eventually leading to comprehensive insight into the differential 
function of genes depending on the site of expression. Whole genome expression 
profiling data for the adrenal is already available, revealing the entire set of candidate 
genes for targeted mutagenesis in the adrenal (Zhang et al., 2004). As Else and 
Hammer state in their 2005 review (Else and Hammer, 2005): “The founder of 
modern anatomy, Vesalius, overlooked the adrenal glands, and, even after the first 
description by Eustachius in 1564, it took almost another 300 years until Addison’s 
description of adrenal insufficiency and Brown-Sequard’s first scientific investigations 
of the organ elucidated the vital functions of the gland. The future looks bright for 
many years of discovery, with basic and clinical investigations beginning to unravel 
the genetic and molecular underpinnings of adrenocortical development and 
disease.” Despite all the difficulties with their generation, adrenocortical cre mice will 
contribute their share to this bright future of discoveries. 
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6 Summary 
 
The stress reaction of mammals is controlled by the hormones Corticotropin-
Releasing Hormone (CRH), Adrenocorticotropic Hormone (ACTH) and Cortisol, 
which are released by the constituents of the Hypothalamus-Pituitary-Adrenal Cortex 
axis (HPA axis). An exact regulation of this system is of essential importance and is 
mainly achieved by negative feedback loops. A dysregulation of the HPA axis is a 
prominent feature e. g. in affective disorders. To investigate HPA axis functioning in 
vivo, mouse models may be used that either do not express (“knock-out” mouse) or 
overexpress key molecules of the system. Observing the consequences of these 
manipulations allows to infer the function of the modified component. However, the 
inference of a molecule function in a certain tissue may be hampered by its function 
in another tissue. 
 
The cre/lox-system offers a solution to this problem. The DNA-recombinase cre 
catalyzes the recombination between two short DNA-sequences, termed lox-sites. 
This property is used in mouse genetics to obtain spatial control over DNA-
recombination. To this end, a mouse expressing cre in a certain tissue or celltype of 
interest is bred with a mouse, in which the genetic region of interest is flanked with 
lox-sites. In cells where cre-protein is expressed and has access to the lox-
sequences, recombination occurs, while the genetic sequence in all other cells 
remains unaltered. In addition to spatial control, temporal control over DNA-
recombination can be achieved by means of inducible cre-recombinases allowing 
e.g. the indepent evaluation of molecule function in different stages of organismic 
development. However, there are currently no mice available that selectively express 
cre-recombinase in the adrenal cortex. Aim of this thesis therefore was the 
engineering of genetical constructs that allow the generation of mouse that 
selectively express cre-recombinase in the adrenal cortex. 
 
In order to restrict expression of cre-recombinase to adrenocortical cells, the classical 
strategy of “knocking in” the cre-coding sequence into the open reading frame of an 
endogenous gene, in our case the receptor for ACTH, was chosen initially. This 
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approach permits gene expression according to the properties of the promoter of the 
endogenous gene. Corresponding constructs were generated for a constitutively 
active variant of cre and a tamoxifen inducible form (CreERT2). These constructs 
were used for homologous recombination in murine embryonic stem cells (ES-cells). 
A neomycin selection marker was integrated via an self-excising cassette designed in 
our laboratory. One ES-cell clone with supposedly correct integration of CreERT2 
was selected to generate mouse line ACTHR-CE2. Unfortunately, the 
characterization of this mouse line revealed no presence of cre neither on RNA level 
nor on protein level, so that breeding was discontinued. 
 
In a second, entirely novel approach targeting constructs on the basis of the 
abovementioned cre-variants integrated into cosmids carrying genomic DNA from the 
ACTH receptor locus were generated by means of homologous recombination in E. 
coli. In these constructs, the gene for the Venus fluorescent marker was introduced in 
order to improve visualization of cre expression domains. The fluorescent marker will 
be translated from cre/Venus bicistronic RNA by means of an internal ribosomal entry 
site. With the cosmid-based constructs mice can be generated either by classical 
“knock-in” through homologous recombination in ES-cells or as transgenic mice by 
means of pronuclear injection. 
 
In the discussion section of this thesis, the justification for the use of the endogenous 
promoter of the ACTH receptor to restrict cre-expression to the adrenal cortex is 
given. Secondly, the choice of cre-variants used in this thesis is discussed. Why the 
self-excising cassette employed in the initial strategy did not function as expected is 
considered next. How an aberrant gene-targeting event lead to the generation of the 
ACTHR-CE2 mouse line is subsequently discussed with a special focus on the use of 
F1-hybrid ES-cells and the effect of non-isogenic DNA in homologous recombination. 
It is outlined, how the novel cosmid-based constructs serve to increase 
recombination efficiency. In addition, the rationale for the integration of the 
fluorescent marker is given. Which steps have to be taken towards the generation of 
mice from the constructs generated in this thesis is delineated next. In an outlook, the 
discussion section points out several possible applications of adrenocortical cre mice.
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7 Zusammenfassung 
 
Die Stressreaktion von Säugetieren wird maßgeblich durch die Hormone 
Corticoliberin (CRH), Adrenocorticotropes Hormon (ACTH) und Cortisol beeinflusst, 
welche von den Strukturen der Hypothalamus-Hypophysen-Nebennierenrinden-
Achse (HHN-Achse) ausgeschüttet werden. Eine genaue Regulation dieses Systems 
ist dabei von entscheidender Bedeutung und erfolgt nach klassischem Modell vor 
allem über negative Rückkopplungen. Eine Dysregulation dieses Systems ist ein 
bekanntes Phänomen u. a. bei affektiven Erkrankungen. Zur Untersuchung der HHN-
Achse in vivo werden Mausmodelle verwendet, bei denen zentrale Moleküle des 
Systems entweder überhaupt nicht („knock-out“-Maus) oder aber vermehrt 
(„überexprimierende“ Maus) gebildet werden. Aus den Auswirkungen einer 
derartigen, selektiven Veränderung kann auf die Funktion der veränderten 
Komponente geschlossen werden. Dabei gilt jedoch die Einschränkung, dass die 
Auswirkungen der Veränderung in einem Gewebe die Interpretation der davon 
unabhängigen Auswirkungen in einem anderen Gewebe verunmöglichen kann. 
 
Eine Lösung dieses Problems bietet das cre/lox-System. Die DNA-Rekombinase cre 
katalysiert die Rekombination zwischen zwei kurzen DNA-Regionen, die als lox-
Sequenzen bezeichnet werden. In der Mausgenetik wird dies u. a. genutzt, um 
räumliche Kontrolle über DNA-Rekombination zu erreichen. Eine Maus mit cre-
Expression in einem bestimmten Zelltyp oder einer bestimmten Region wird mit einer 
Maus gekreuzt, in der ein bestimmtes Gen von Interesse mit lox-Sequenzen flankiert 
worden ist. Nur in den Zellen, in denen cre-Protein gebildet wird und Zugang zur lox-
markierten DNA hat, kommt es danach zur Rekombination. Die genetische Sequenz 
in allen anderen Zellen bleibt unverändert. Neben dieser Möglichkeit zur räumlichen 
Kontrolle lässt sich mit Hilfe von sogenannten induzierbaren cre-Rekombinasen auch 
die zeitliche Kontrolle erlangen, was die Differenzierung der Funktion von 
Genprodukten z. B. in verschiedenen Entwicklungsstadien erlaubt. Z. Zt. gibt es 
jedoch noch keine Mäuse, die cre-Rekombinase selektiv in der Nebennierenrinde 
exprimieren, mithin also die Untersuchung der Genfunktion in diesem integralen 
Bestandteil der HHN-Achse erlauben würden. Ziel dieser Arbeit war deswegen die 
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Erzeugung genetischer Konstrukte zur Herstellung von Mäusen, in deren 
Nebennierenrinde cre-Rekombinase exprimiert wird. 
 
Zur Restriktion der Expression der cre-Rekombinase auf die Zellen der 
Nebennierenrinde wurde zunächst eine klassische Strategie des „knock-in“ der cre-
kodierenden Sequenz in den offenen Leserahmen des ACTH-Rezeptors verfolgt, um 
dadurch die Eigenschaften des endogenen Promoters dieses Gens auszunutzen. 
Entsprechende Konstrukte wurden sowohl mit einer dauerhaft aktiven cre-Variante 
als auch mit einer Tamoxifen-induzierbaren Variante (CreERT2) erstellt. Diese 
Konstrukte wurden für den Austausch der Wildtyp- durch die rekombinante 
Genkonfiguration durch homologe Rekombination in embryonalen Stammzellen (ES-
Zellen) der Maus eingesetzt. Die für die Selektion als Marker notwendige 
Neomycinresistenz wurde dabei in einer in unserem Labor entworfenen, selbst-
ausschneidenden Kassette integriert. Ein Stammzellklon mit vermeintlich korrekter 
Rekombination mit dem CreERT2-tragenden Vektor wurde zur Erzeugung der 
ACTHR-CE2-Mauslinie verwendet. Die Charakterisierung dieser Mauslinie ergab 
jedoch sowohl auf RNA- als auch auf Protein-Ebene kein Vorliegen von cre, so dass 
die Zucht der Linie eingestellt wurde.  
 
In einer zweiten Strategie wurden mit Hilfe homologer Rekombination in E. coli mit 
den bereits zuvor verwendeten cre-Varianten neuartige Konstrukte auf Grundlage 
eines ACTH-Rezeptor-Genlocus tragenden Cosmids generiert. Zur Verbesserung 
der Darstellbarkeit der cre-Expressionsdomänen wurde in diese Konstrukte zudem 
das Gen für den Venus-Fluoreszenzmarker eingeführt, dessen Translation mittels 
einer „internen ribosomalen Eintrittstelle“ (IRES) von bicistronischer cre/Venus-
mRNA erfolgen soll. Die Cosmid-basierten Konstrukte eignen sich sowohl zur 
Erzeugung von Nebennierenrinden-cre-Mäusen durch homologe Rekombination in 
ES-Zellen im Sinne eines „knock-in“ wie im zuvor verwendeten Ansatz als auch zur 
Generierung von transgenen Mäusen durch pronukleäre Injektion. Der Einsatz eines 
Cosmids als Vektor zur Generierung von Mäusen ist dabei ein neuartiger Ansatz. 
 
Im Rahmen der Diskussion wird zunächst dargestellt, dass die Verwendung des 
endogenen Promoters des ACTH-Rezeptors geeignet für die Restriktion der cre-
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Expression auf Nebennierenrindenzellen ist. Des Weiteren wird die Wahl der 
benutzten cre-Varianten diskutiert. Mit Bezug auf die initial erstellten, klassischen 
„knock-in“-Konstrukte wird erörtert, warum die verwendete Selektionskassette sich 
nicht wie gewünscht selbst exzidierte. Im Anschluss wird diskutiert, warum auf 
Grundlage von erst post hoc erkannter, aberranter Rekombination die Generation der 
nicht-funktionalen ACTHR-CE2-Mauslinie erfolgte. Besonderes Augenmerk wird 
dabei auf die Verwendung von F1-Hybrid-ES-Zellen und nicht-isogener-DNA für 
homologe Rekombination in ES-Zellen gelegt. Sodann wird der Frage 
nachgegangen, wie mit Hilfe der neuartigen Cosmid-Konstrukte die Effizienz des 
Rekombinationsprozesses erhöht werden kann. Ergänzend wird die Verwendung des 
zusätzlich eingeführten Fluoreszenzmarkers erläutert. Es wird dargestellt, welche 
Mauslinien mit den vorliegenden Konstrukten generierbar sind und welche weiteren 
Schritte dafür notwendig sind. Abschliessend erfolgt ein Ausblick auf mögliche 
Anwendungsbereiche. 
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